English-Arabic
English-Arabic
acetylcholine (,# 8 B > ) J 2 A acetylcholinesterase ( ) J 2Q 2 acid !& a-DNA ,/ !& / a acidic fibroblast growth 01 : & 01 $ 0 & , &N & B *2JQ Z @ & ,/ factor a acidosis 0 : & a-helix $ ,# acquired immune E 2 J & ,# B & " 0 & & a-linolenic acid a ; !& deficiency syndrome ab initio gene prediction 0 & SG & E J `. acquired mutation 0 2 J & 9 $ H ABC transporter 0 ; > ABC 3 CG & acro-cyanosis HQ = abiogenesis #* W / ,# % -N acrylamide gel & JQ U abiotic ,/ < / ,# ] actin (,# ; : B ) J abiotic stress ,/ < A * activated charcoal H6- & ,# ablation % * / 8 $ activation energy H - 0 > H abrin !" # # $ %) activator H+- & ( % active immunity 0 ; B 0 B & abscisic acid 2 2 ] !& active immunization 0 ; B 0 B & E 2 J absolute configuration = ; H & ` A active ingredient 0 ," 91 & absorbance (Z 8 &M 7;B 9 N>) ,Z & active site H - D : & absorption Z 8 & active transport ," @ abzyme 01 & Z 5 % ,/ , : & activity coefficient H -6 & " & 9 +$ & acuron TM gene TM J SG & acceptable daily intake @ & ,# & 5 & acute exposure , !. " acceptable level of risk @ & 9 H 5 & T 2 & acute illness 91 06; B acceptor G @ & acute sample 91 0 G B acceptor control G @ & WJ acute toxicity 91 01 G& 2 acceptor junction site G @ & 8 + , @ & acute transfection , " accession N> 0 @ & / 0 : acyl carrier protein 2Q > accident ! B / S acylcarnitine transferase 7 J 2Q accidental release ,# : B J acclimatization 0 & ;> adalimumab ( ) E & & accumulation K J / NJ adaptation 0 &VI & / . J acetolactate synthase 3 J] 2Q D 8 adaptation traits 0 $ G J & 3 $ 8 acetone 0 ; I 2 01 I & J 91 &) 2 adaptive enzyme ,# &c` (,/ : B E % &J 5 2N adaptive radiation ,# & c` "- acetyl carnitine J 2 adaptive zone 01 & c` 0 @ H & acetyl co-enzyme A A ] = & 2 additive ,# " & * / : & acetyl-coA A 2Q = & additive effect : & CP acetyl-coA carboxylase = & ; 2J J additive genes (0 : &) 01 ".& * 3 CG & A 2Q adenilate cyclase ,/ Q =+; &
73 English-Arabic
3 $2 $ adenine (01 * 9 B >) aerosolization E : 2 adenosine 6J 2 D& H & ) aerosolize(d) E : (/ aerosolized biological EG : & ,/ & B adenosine diphosphate 3 $2 $ ,# I NC agent adenosine 3 $2 $ ,/ aerosolizing E : monophosphate afebrile 71& E 8 & < adenosine triphosphate 3 $2 $ ,# C NC affected part E 8 & * adenoviridae 0 1 1 N< 3 2 affinity 0 $ adenovirus 0 1 1 N< 0 2 affinity chromatography E - 2 adequate intake X J % 5 affinity tag 0 $ 0 & B adhesion molecule ( I ) = 8 e * aflatoxin 01 HN 3 ; @ 2 &) 2 J N V adhesion protein = 8 ( J ; 0 H 2 & 01& 2 adipocyte 01 & - 0 1 ; 5 agar * adipose ,# U / ,# & - agarose * adjuvant 9 B 2 & 91 & agarose gel / * ,# & U ,# A J adoptive cellular therapy 76 & ,/ ; 5 4 B electrophoresis adoptive immunization 9 6 & 0 B & age group 01 & B 0VI adrenocorticotropic YNJ 9 - @ [G* & & U agent & B hormone agglomeration . J adsorption Z 8 & agglutination HW; * / ,Z adult stem cell 0 R 01 B % * 5 agglutinin ( 1 8 & # 018 ) ;* advanced informed ? @ 2 & A B ; " & 01 > $+ aging & & @ / f. - agreement aglycon ; & a ) ,/ 6J 2 ] * adventitious ,# : B / ,# 1 ( J ;* e * adverse effect , : C aglycone ; & a ) ,/ 6J 2 ] * adverse reaction , : B $ ( J ;* e * aedes albopictus 2 ) ! VQ 0 H6@ & 0 * B 1 agonists B 2 & ,# I & B (0 : " ; ,# & ; B agraceutical ,# B : 2 & aeration 0 A agriceuticals 01 B 3 : 2 & aerobe ,# I A / ,# I agricultural 0B 7 E 2 &) ,# B aerobic *2JQ i " & / ,# I ( A 86 aerobic bacteria 01 I U J agricultural biodiversity ,# B ,/ . aerodynamic 01 I A J & G ; B agricultural biological ,# B ,/ . (3 & M ) diversity aeromonas 0; 8 & C * K *) 01 < agrobacterium ( J & K *) 01 B * (3 1 &: agrobacterium 0 & & 01 B * aerosol E : tumefaciens aerosol particle E 1: 2 * agrobiodiversity ,# B ,/ . aerosol spray ,# : L 65 agrobiotechnology 01 B 01 3 1 @ aerosol vulnerability ,# : WCP 0 B 2 5 agroecology ,# B 0VI ; B 74 English-Arabic agroforestry ,# B 4 ; B allopatric speciation H 6 5 0 * . AIDS @ Z@ 0& &) ] allosteric enzyme ,# < $ (0 2 J & 0 B & allosteric site ,# < $ D : & air U allosterism (allosteric) & 0 " . R ) g $ air america compressors A H R : 0 < T 5 91 & [H airborne pathogen EG 2 & / A @ 0 : & & ([ J A @ ,#: & allotypic monoclonal L 2 2M 01 91 : & 2* airborne precaution A @ & & antibodies ,# ; H & 3 % airbrush A H R : & " 9 - N allozyme ,# $ 5 airplane 9 I H α amylase inhibitor-1 ( ) ; & $ HG C & airway ,# I U ; 2 & α galactoside $ J] * alanine (# & !& ) ] α helix $ ,# alanine aminotransferase ( ) ] & > α interferon $ albumin & # * ) & α linolenic $ (E ; d! ! d 1 α particle $ 2 * aldose 9 & 7 ; B & - 6J 2 ) V α-chaconine $ J - ( U α-helice $ E aleukia ! 3 1 NJ 9 α-rumenic acid !& ) $ & !& aleurone # #I %< J & ) (,/ " & (0*: E α-solanine $ ] 2 alfafa 2 α-synuclein $ ;J 2 algae E H α virus $ 3 2 algal toxin ,# N; NH $ % als gene als SG & algorithm 01 & N5 alternative medicine 4 B alicin 0 B & " @B) 2 alternative mRNA 2 +$ : & ( C 0 8 N5 & J splicing alien species 0 < 01 : B alternative splicing $ : alkali ,/ ; > alu family alu 0 ; I B alkaline ,/ ; > aluminum & Q 8 B alkaline hydrolysis ,/ ; > ,# I & ; / 01 ; > 0 A & ; aluminum hydroxide & Q 2J U alkaline phosphatase ( ) 01 ; > $2 aluminum resistance & O @ & alkaloid ,# ; > aluminum tolerance & O G& & allele (91 : & 3 1 R_ 8) aluminum toxicity & Q 01 G& 2 allelic exclusion ,# ; 8 > alveolar macrophage ,# 5 2 " ; allelopathy 8Q ,# H C Alzheimer's disease & U ! & allergy (K.2 6 H ) 01 * V ambient measurement H & K @ & allicin ,/ H ,/ , : & ) 2 american type culture (ATCC) 0 & 6Y & 2 ( C & Z ; 5 2 ,/ > collection allogeneic X3 ) ,# $ 5 / 3 CG & ; 5 & ames test F2& &8 E ;2 ) K& 5 ( 6 K $ & 5 & 9 & 0 I 0 I & J & allopatric H 6 ; 5 & (3 $H; 75 English-Arabic amino acid ,# & ! & analgesic +J 2 & amino acid profile ,# & !& D H @ & analog ] 3 H " & / [ - &/ b U : & amino acid sequence ,# & !& E 01 & > aminocyclopropane ;J 2 &Q !& analog gene b U : & SG & carboxylic acid ; 2J J analogous 0 $ Y [ - & / b U : & aminocyclopropane !& D 8 analogue b U : & carboxylic acid synthase ;J 2 &Q analysis of variance 6 ; ; 2J J analyte ( A; ; / * 91 &) 0 ; ; aminopyridines & anaphylatoxin +$ N &2) ,# > P $ % aminotransferases &Q 0 B & * & @ 3 & (01 2 2 amphibolic pathway & J 8 ) K J " & ; 2 & anemia 1 @ (,# : Q A anesthesia ,K H / a / 5 amphipathic molecules &. 0 ; @ & 3 VI * aneurysm ( &2 ) 1 , amphiphilic molecules 0 U J 01 & 01 HN> 3 VI * angiogenesis 0 B VQ W &; angiogenesis factor 0 B VQ W & B amphoteric compound ,Z 5 D6 & ) E % % & E6J & angiogenic growth factor P - & ,# I B , & N & B (91 : & angiogenin # N5 B) * * amphoteric electrolyte E % % & A J (0 B Q W 0 ;&B ampicillin D 2 ,/ , : & ) ; 2 & angiostatin HG C & ) 2 * ( 6H (01 &1 0 B Q amplicon A* & 0 * D H >) 65 : & angiotensin-converting 2 * Q G & ( 5 :6 01 @ PCR enzyme amplification 5 : angiotensin-converting 2 * Q HG C & amplified fragment G " & 65 : & * NH enzyme inhibitor length polymorphism J-Q angstrom / 2 H 9 ) 2 R 8 (AFLP) 7;B 0 ] ; &" 2 2 10 amplify +5 : (0 I * " Q amplimer B : & animal genetic resources 01 C 8 & 3 & ;" & amylase -6 H- #&:U ) & databank 01 ( & & R8 3 7 animal genome (gene) 01 3 CG & amyloid plaque # DG& * & ,/ - [ - bank ! B &) 01 8 " 5 animal model ,# 4 % & ( & U ! & anion (0 - E 2 ) amyloid precursor protein ,/ - [ - ,# anneal ( " & ) #+@ 2 / G H amylopectin ( -6 ) J ; & annealing (9 ) ; amylose ( -6 ; ,#;5 G J & ) N; & annotation 01 2$ 0 - / % anabolism ( ) ,# I ! anonymous DNA marker A * & +; " & anaerobe ,# I U ] antagonist 91 : anaerobic ,# I U ] anterior pituitary gland 01 & & 01 & 5N 91 N< anaerobic bacteria 01 I U] J anthocyanidin (01 01 < 8 91 &) 2 C anal ,# * - anthocyanin (01 01 < 8 91 &) 2 C 76 English-Arabic anthocyanoside U Q # 0 2Q = > antihemophilic globulin =W; " ) B 6 , : & ;< anti-idiotype ,# % H &6 HG C & ( 1 anti-idiotype antibody ,# % H &6 HG C & , : & 2 * antimateriel agent 91 & , : & & B anti-infective T " , : & antimicrobial agent 3 J & , : & & B anti-infective agent T "; , : & & B antioxidant 2 JP D & anti-interferon HG C & antiparallel / 6 ,# 2 J B anti-o-polysaccharide 3 1 6J.2 B HG C & , : & 2 * antiplatelet 3 $18 , : & antibody ,#B & < antiporter ) ,# 2 NJ " & , : & anti-oncogene 01 & 3 CG & HG C & B J & 0 :K J " & anti-sense technology K 2 M D & 3 1 @ ( G : & U * -R antiangiogenesis 0 B Q W , : antiproliferative ,/ NC J D & antibacterial 01 J C * , : & antipyretic 7 1& , : & antibiosis ,/ , : antisense ,# @ H & < antibiotic ,/ , : & antisense RNA ,# @ H & < antibiotic resistance ,/ , : & @ & antiseptic GA H & antibiotic therapy ,/ , : & a " & antisera 8 & , : & antibiotics 01 3 1 : & antithrombogenous 1 WC 5 , : & C J & antibody , : & 2 * polymer antibody affinity 0 $ Q , : & 2 * E - 2 antitoxin $ +% , : & chromatography antiviral 3 2 , : & antibody array 91 : & 2 * 0 & Y & antivirial agent 3 2 , : & & B antibody-laced nanotube 0 -
( 1 H 2 0 8M bile acid $18 !& bcr-abl genetic marker J& ) bcr-abl 0 1 C 0 & +; " & bilirubin ( $18 E : 5) ; 0"- 5 2 A ` binding site H 1 ; 9 1 & 0@H &) H 1 D > & FISH 0 @ K 2 ;$ (T 5 3 I * D& 3 CG & D> & J& bio 9 # " 0VI (3 % D> & %A 0 2 T 5 bio reactor ,/ B $ & bed 0 J 2 & / 2 bio-bar code ,/ 6$ - & H 5 behavioral epidemic ,# J ; 2 bioaccumulant ,/ J & benchmark concentration 01 " : & 0 & " J bioaccumulate ,/ J benign S 5 < / & bioaccumulation ,/ NJ benthos H & > bioactivity ,/ H - bequest value 0 8 S M 0& > bioassay ,/ ,# & J @ / 01 0 2 @ & bess method K 0 @ H bioaugmentation ,/ bess t-scan method K 0 @ H t F 2 & bio availability ,/ N best linear unbiased < ,# H 5 `. : biocatalyst G 2N 91 &) ,/ +$ & prediction (BLUP) & (01 3 ;&" β carotene J biochemical ,/ ,# I & J β cells 5 biochemistry 01 & J ; B β conformation J biochip 01 0 > > β interferon (3 2 , : & ) biocide ,/ & β oxidation 2 JP biocoenosis ,# I D& * & β sitostanol 2 2 bioconcentration factor ,/ J & B β sitosterol 2 2 biodegradable ,# I Q W; 6 ; > β -conglycinin 2 * J biodegradation ,/ W; β -d-glucuronidase ) J ;* n biodesulfurization ? 1 3 J 0 J- J ;* ; +$ & biodiversity ,/ . ( bioelectronics 01 3 1 J β -DNA bioenergy 01 0 > H β -glucan J ;* bioengineering 01 0 2 U β -glucuronidase J ;* n bioenrichment ,/ < β -lactam antibiotic , : & ) J] ,/ , : & biofilm ,/ ; (,# ; 2 ,/ biogenesis ,/ - N β -lactamase ,/ J ) & J] biogeochemistry 01 & J * 01 3 1 : &; 0 & @ & A;"* biogeography 01 R * (01 ; 2 biohazard ,/ H 5 β -secretase ( ) J 2 bioindicator ,/ +- V` & bifidobacteria 01 I NC 01 J 01 ; 5 bioinformatics 01 01 & ; " & bifidus & 2 > 7 = @ - & bioinorganic ,/ ,/ : B < bifurcate "N- 7 2 @ bioleaching ,/ F - bile J; #2 2Q M ) $18 biolistics 5 3 CG &; ,# > @ (9 & # 5 5
80 English-Arabic biologic agent ,/ & B biological shield ,/ B biologic indicator of 0:G " & 0 2 & ,# I biological stressor ,/ A * & exposure study biological threat ,/ A biologic monitoring ,/ E > & biological threat agent ,/ A & B biologic response 0 * " & ; 0 6 0 * 2 G " & biological transport ,/ @ modifier therapy biological uptake ,/ % 5 biologic transmission ,/ @ biological vector ,/ > biologic uptake ,/ % 5 biological warfare 01 * E / 01 E biological ,# I biological warfare agent 01 E & B biological activity ,/ H - (01 * ) biological agent ,/ & B biological warfare agent 01 E & B 8 biological and toxins 01& 2 01 0 ; 2 01 > $+ classification (01 * ) weapons convention biological warfare agent E & B 7;B . "6 0 @ H (BWC) identification method (01 * ) 01 biological attack ,/ * U biological weapon (01 * ) 01 0 ; 2 biological contamination ,/ S . ; biologics ,/ biological control ,/ WJ biology 9 ; B / Q ; B biological control agent ,/ WJ & B bioluminescence ,/ = W P biological defense 01 0 & @ & biomagnification ,/ J biological diversity ,/ . biomarker ,/ +; " & biological effect ,/ C P biomass 01 I 0 C J / 01 0 ; NJ biological emergency ,/ e H biome 0VI / 01 0 @H & biological environment 01 0VI biomedical testing ,/ ,# H Z biological half-life ,/ 9 8 biomim ,/ +; @ & biological half-time ,/ 3 > 8 biomimetic material 01 9 +; @ & 91 & biological incident ,/ ! B biomodulator ,/ 4 % & biological integrated ,/ & J & - J Y biomolecular electronics 01 01 I * 3 1 J detection system biomolecular engineering 01 01 I * 0 2 U biological marker ,/ 8 / 01 0 &+; " & biomonitoring 01 0 > & biological marker of - J; 01 0 &+; " & biomotor ,/ G & exposure bionics 01 3 $G8 = H ) J biological measurement ,/ K > (0C 3 1 @ 7;B biological medium ,/ H 2 biopesticide ,/ ,/ - & biological molecule ,/ e * biopharmaceutical 0 6, 3 1 ] 8 biological monitoring 01 0 > & biophysics 01 " H / 01 biological operation 01 01 ; & B biopolymer ,/ C J & biological oxygen ,/ * 2 J E ; H biopreparat 01 2 01 0 ; 2Q 0 &6Y & demand bioprocess 01 01 ; & B biological resource 01 8 & bioprocessing 01 0 ; & " & biological response 01 0 * 2 _ G " & biopsy (,# a 2 0 B Z ) 0 B N5 modifier bioreactor ,/ B $ & 81 English-Arabic bioreceptor ,/ @ 2 & blast cell 01 & 01 ; 5 biorecovery 01 9 " 2 blast transformation ,# & bioregion 01 0 @ H & blood clotting 1 WC 5 / 1 HW; * bioregulator ,/ +Y & blood derivative 1 = - & bioremediation 01 0 * " & blood plasma 1 & biosafety ,/ & blood platelet 1 F I $ 8 biosafety level ,/ &Q T 2 & blood serum 1 8 & biosafety protocol ,/ & a A & blood-brain barrier g &G , * bioseed 01 % blower L $ & biosensor K 2 9 A * ) ,/ ,K * & blunt-end DNA 0 @ ;R & 0 A+ % (,/ blunt-end ligation H / 0 2 & 3 A+ H biosensor technology ,/ ,K * & 3 1 @ 0; ; J 0 A+ biosilk ,/ boletic acid !& biosorbent 01 018 & 91 & bollworms HN@ 9 biosphere ,# H &) ,/ < bomb 0 ; N> (! O bone morphogenetic Y " J - biosphere reserve ,/ < * protein biosynthesis ,/ = ; 5 bottle 9 > biota 0@H & 3 ) 3 1 botulin toxin 7;B +CV` $ %) $ % ( A (E 8BQ biotechnology 0 1 3 1 @ botulinum 01 I U ] 01 8 B J ) 01 @ - bioterrorism ,/ E U ( $N bioterrorist ,/ ,# U botulinum toxin 1# @ - $ % biotic ,/ botulism ' $N $ %) ,#@ * 2 .& 2 biotic resource ,/ 8 & 0&"HQ !" # * 01 @ - biotic stress ,/ A * (052$ & biotin & # E 1 % & ) bovine somatotropin 0 AG* &) ,# ,/ G , & N & U (B 3 & EJ & 7 #& (01 2 * biotinylation D& 3 VI * H 01 ; & B bowel " & A : " bowman-birk trypsin n & 2 HG C & biotope 9 1 & 01 0@ H & inhibitor biotransformation ,/ BP (base pair) 4 Q B) 1 K > 9 biotype ,/ H & ( B @ & biowarfare (01 * ) 01 E bradykinin J bioweapon (,#* ) ,/ \ 2 bradyrhizobium 0 G C & J ) J * 9 % * & biphasic 0 ; & ,# I NC japonicum (0 N # * bipolar ENHN@ ,# I NC branch 8N< / bivalent `N J6 ,# I NC brassica & 3 / ) E J - $ ; & bla gene bla 0 CG & (3 1 ;8 0; 8 black-layered 0 @ H , 2 & brassica campestre 3 $ black-lined (,/ H ! &) ,# H 5 2 brassica campestris 3 $ 82 English-Arabic brassica napus 3 $ c brazzein (,# ,# #+; &) c-kit genetic marker c n @ H 01 C 0 &+; " & brca 1 gene brca 1 0 CG & c-reactive protein c n B $ & brca 2 gene brca 2 0 C G & cadherin 0 @ 8] 3 ) J brca gene brca 0 C G & ( 5 breakdown 2 J caffeine I J breed 0 2 calcium 2 J 8 B breed at risk 9 HN5 0 .2 2 calcium channel-blocker 2 J 9 > = ; R & breed not at risk 9 HN5 0 .2 2 calcium oxalate 2 J 3 ;2J breeder's rights G2 & = @ callipyge EG 2N #- & # 9 $ H) a J breeding 0 / 2 (0 ; & Q brevetoxin & $ % callus ( & & < ,/ ; 5 a 2 ) % - bright greenish-yellow , $ 8 & : 5 =W P calmodulin H ) & J fluorescence ( 2 J broad spectrum ! B H / D 2 H calomys colosus ,# * Q @ P broad-specturm D 2 H calorie ,/ " 2 / / J bromoxynil / E -B & calpain-10 10 – J bronchi 01 I U 3 8 > / 01 I U E "N- Campbell Hausfeld ; $2 U & J bronchial 01 I A E "W- =+; " & campesterol (# 2) 2 & J broth ,#B = & campestrol (# 2) 2 & J brown stem rot E 8 ,/ H ! &) & 2 W$ " camphor N J 3 & &2M 3 campsterol (# 2) 2 & J (0*2 Q camptothecins , : & #I C & J) C 2 & J bubonic plague 91 NR E 8 ) ,# ; B H ( H 12 (01 $& ; canavanine J bucket N cancer H 2 buffer zone 0VI 0 @ H & cancer epigenetics H 12; # & =W; 5 buffy coat A - 0 < canda J bulk # " & * cannabinoid [ - EJ &) J bulking D & * ( J bunyaviridae & 0; 8 ) 01 3 2 canola ] J (3 2 $ capable of being 5 7 Z 5 - & [ @ J & burn-through range T & = transmitted from one bxn gene bxn 0 C G & person to another capacity 9 N> / 0 " 2 C capacity building 3 N@ capillary electrophoresis 8 / ,/ " - ,# I A J c value (cellular DNA ,/ ; 5 0 & > = > ,# I A J value) capillary isotachophoresis ,/ " - D 2 / 2 & c-DNA ,/ !& / c capillary isotechophoresis ,/ " - / 2 & *2JQ Z @ & ,/ capillary zone 0@ > 0@H & # ,# I A J 83 English-Arabic
electrophoresis catabolite repression 0 :G @ & 3 J capsid = I > ,# < ) 0 ; B catalase ( ) ] J (K $ catalysis $ capsular 0 ; B # Y $ &) ,# Y $ & catalyst 9 $ 91 & (0 2 J catalytic antibody 9 +$ & 91 : & 2 * capsule 0 Y $ & catalytic domain +$ & * & captive breeding 1 @ & 2 catalytic RNA +$ & capture agent M & B catalytic site +$ & D : & capture molecule M E6J & catechin (0 : > 91 &) J J carbetimer , : & ,# B 8 & ) & J catecholamine & 0@ - & 3 6J &) &] J J ( &.2; Q C& J J carbohydrate 3 U J (,# 8 " A * 7;B CV`N carbohydrate engineering 3 U J 0 2 U cation (0 - E * & ) J carbon dioxide J 2J # C causative agent ! & EG 2 & carbon nanotube ,# J ,/ E caveolae ] J carcinogen 91 & / H 12; 9 + & 91 & caveolin J 0 H 2 & ccc DNA ,/ I carcinogenicity 0 H 2 cDNA ,# & & carnitine (,# & !& ) J cDNA array G& & E carotenoid # J ^ 8 cDNA clone G& & 0 ; 2 carrier & cDNA library G& & 0 J & carrying capacity & 0 " 2 cDNA microarray G& & & 0 @ > 0 $ 8 & cartilage-inducing factor ,# :N< S & B cecrophin 2 2 cascade - cecropin a a 2 2 case 0 cecropin a peptide a 2 2 case study 0 0 2 cefazolin (,/ , : & ) $ 2 case-by-case 0 0 ceftriaxone & ,/ , : & ) 2J $ 2 case-fatality rate 0 &M 1 " & (3 2 $ 2 0B &*& case-finding 3] /G ceiling limit 7 ; B , / @12 , caseous necrosis (,# * ) ,#* 2 3 & ceiling value ; B 0 & > / @12 0 & > caspases # 0 8 5 ; +H & cell 01 ; 5 5 3 & 01 ; & B cell culture ,/ ; 5 3 2 / 5 0 B cassava (01 - % * % 3 ) 2J cell cycle 01 ; 5 9 / 01 ; 5 9 9 cassette 0 ; B / H - cell cytometry ,/ ; 5 K > cassette cessation 0 ; " H @ cell death 0 ;5 3 &) ,/ ; 5 3 & castor bean 5 % ( A;; # castor oil 5 3 cell differentiation 01 ; 5 & casual contact ,# & 2 < 8+ cell division 01 ; 5 2 @ catabolism ! @ / A ! cell fusion 01 ; 5 4 & catabolit gene activator 0 :G @ & H+- & cell membrane ,/ ; 5 - < protein (CGAP) cell membrane structure ,/ ; 5 - R E J 84 English-Arabic cell nucleus 01 ; 5 9 cetylpyridinium GA H &) 2 cell recognition ,/ ; 5 " (,# " : & cell respiration ,/ ; 5 K W$ chaconine 7;B CV`N 01& 2 91 &) J - cell signalling 01 ; 5 9 - ? " H 9 * & ,# 8 " J & cell size 01 ; 5 * ( H H # 0:$5 & 3 2& cell sorting 5 chakrabarty # J - cell turnover 01 ; 5 . chakrabarty decision # J - > cell-differentiation 01 ; 5 & chalcone isomerase J - g 8 & protein channel-blocker 9 @ = I B cell-free gene expression ,/ ; 5 ] ,# C " Y chaotropic agent 3 a N 91 &) i -6 & B system (,# I * E J 6 +; N cell-mediated immunity 01 ; 5 0 H 2 0 B & chaperone = & cellular adhesion ,/ ; 5 M e * chaperone molecule = & e * molecule chaperone protein = & cellular adhesion receptor ,/ ; 5 M @ 2 & chaperonin 3 WJ - ) - cellular affinity 01 ; 5 0 $ (0 @ & cellular immune response 01 ; 5 01 B & 0 * 2 chapin plant and rose 3 6 9 U1 ; - $ " 0 cellular necrosis ,/ ; 5 3 & powder duster cellular oncogene ,/ ; 5 ,# & S G & character 01 8 5 cellular pathway mapping ,/ ; 5 2 & H H 5 characterization assay 01 $ 8 0 * cellulase H- 7;B > ) ;2 characterization of animal 01 01 C 8 & 8 ( J ;< 7 ; ;2 genetic resource cellulose ; ;2 chelating agent ,# ; 5 & & B celsius 9 K @ &) K 2;2 chelation 0 "& 9 - 8+ ) EN; 5 & (,/ VI & 8 $ M A J & ,/ : B / * center of diversity . 6 J & ( " & [ B centers of genetic ,# C . 6 J & chemical agent ,# I & J & B diversity chemical attack ,# I & J * U centers of origin P - & J & / 8Q J & chemical genetics 01 I & J 0 C centers of origin and . 6 -W 8 & J & chemical molecule ,# I & J e * diversity chemical terrorism ,# I & J E U central dogma 01 J & 9 @ B / ,/ J & & chemical warfare 01 I & J E centrifugation ,/ J & H / % chemical warfare agent 01 I & J E & B centrifuge B I 2 8$ 9 1 0 ) 9 % chemical weapon ,# I & J \ 2 ( & * chemicalization 9P & J centromere / ,/ J & 2 N> / ,# R G8 J & chemiluminescence ,# I & J " & & 2 chemiluminescent ,# I & J " &;6 ,# B & Z centrosome ,/ J & 2 * immunoassay cerebrose ( J] <) 2 chemo-autotroph 01 I & J 0 %R6 ,# % cervical lymphadenitis ,# @ N B ,/ $ & , N< E A chemokine ,# I & J +C V` & ,/ : B " , cassette cessation 0 ; " H @ chemometrics 01 I & J 3 2 > 85 English-Arabic chemopharmacology ,# I & J > @ " ; B cholinesterase H- ) J 2 chemoprophylactic ! & ; ,# I & J # > ([ "$& H C C J chemoprophylaxis ,# I & J ,# I > * chromatid & J / ,# R G8 = - chemotactics factor ,# I & J E % * & B chromatin & J / R 8 chemotaxis 3 I J ) ,# I & J E % * chromatin modification R G8 " (01 chromatin remodeling R G8 0 < 8 chemotherapy 01 I & J & 0 * " & chromatin remodeling R G8 0 < 8 & B chill b * $ & element chimera 0*2 7;B / I J) & 5 chromatography E - 2 / (,#C E J 0$; 5 & chromosomal #& 2 & J / ,/ R 8 & J chromosomal packing 3 1 R G8 0VI " 9 chimeraplasty SG & \ 8 / SG & 0* " & unit A 2 & chromosomal ,/ R 8 ^ chimeric antibody ,/ & J , : & 2 * translocation chimeric DNA ,/ & J chromosome 2 & J / ,# R 8 chimeric protein ,/ & J chromosome map 0 H 5 / 01 R 8 0 H 5 chiral compound ,# & NY 6 B E6J & D: & C &N ) 01 & 2 & J chitin R +J -N 01 > 91 &) J (3 1 R G8 7;B 3 CG & (3 - ; ,#* 5 chromosome painting 3 1 R 8 2 chitinase ( ) J chromosome walking 0 ;+@ & 3 1 R 8 chlorination ( & 0 @ ;J 0 : ) 9 ; J chronic & & chlorine ;J 8 B chronic disease & & ! & chlorine demand ;J E6; H chronic effect & & CP chlorine dose ;J 0 B * chronic heart disease & & E ; @ ! & chlorine residual ;J 3 +@ & chronic intake & & % 5 chloroform ;J chymosin E ; WC 5 ) 2 & J chlorophyll 3 R 8) ;J / : 5 ( 2 0$ Y A : 5 01 cidofovir , : & ) 2 = ;5 0 ;&B # 0 I 1: 0> H ( 5; 0&+5: & 3 2 $; (#I : cilia (01 U I ) E U chloroplast 01 01 ; 5 / : 5 0 ; * ciliary neurotrophic ,# U ,# 8 B & B / ;J 7;B / factor : 5 3 2 cis-acting protein ,# N% * H - % chloroplast transit peptide 3 2 ; ,/ B cis/trans isomerism @6 g 8 : 5 cis/trans test 5 / = $ & @ & 5 cholecalciferol $ 2 J J N EN% * cholera toxin J $ % cisplatin ( O , : & ) 2 2 cholesterol 2 J cistron 2 2 cholesterol oxidase 2 J 2JP citrate synthase 3 2 D+ 8 & choline $18 # 91 &) J citrate synthase gene 3 2 D+ 8 & SG & (,#$ Y J Q 01 : citric acid ( & ; !& ) 2 ! & 86 English-Arabic citric acid cycle 2 !& 9 cohesive ends 0 @ 01 > 8 3 A clade 3 $G8 # [ - 3] 2 cohesive termini 0 @ 8] 0 A 2Q B 0 C & 01 C cohort 0 B & * / 01 cladistics 3] .2 . H 8 cohort study E Q 0 2 clathrin (HW; *6 ; 91 : & 91 &) C J colchicine D & / ;> E6J &) 2 - J climate change ,# 5 & R C 0 R& H 5 . J climax community 9 W% D & * & (0 ;5 2@ clindamycin (,/ , : & ) 2 & ;J cold acclimation 9 N; >P clinical trial 0 1 2 0 * cold acclimatization 9 0 & ;> clone 0 ; 2 cold hardening 9 #G2 @ cloning 2 / L 2 2 cold tolerance 9 .& clostridium ( J & K *) 01 +C H & cold-shock protein 0 & 8 clostridium perfringens 0 & H N01 +C H & $ % colicin !" ' $ ) 2 J toxin (0 @ C * clubbing .* " coliform organism 01 N> J cluster @ B collagen (#$ ) *] J cluster of differentiation 9 & & 5 & 0 B & * & collagenase :A ) *] J clustering N@ " ( *] J co-adaptation 0 & 0 &VI & collodial - < +; 5 = I 2) J co-chaperonin WJ - ) - B 2 & ( & , : (0 @ & 3 colloid 01 < 91 & co-enzyme ] B 2 & colloidal ,# < co-evolution - & . H / / 2 & -N colloidal electrolyte ,# < A J co-factor B 2 & & B colonial morphology J6- ,/ & " 2 & co-factor recycle 6 B 2 & & B colony 9 & " 2 & co-management 9 M B 2 & colony hybridization ,/ & " 2 & * A co-repressor HG C & B 2 & colony stimulating factor 3 & " 2 & +$ & & B coagulation HW; * / WC 5 combinatorial coat protein ,# < combinatorial biology 01 $ * coated vesicle 6; R & * / 0 $6; R & 0 ; 8 combinatorial chemistry 01 $ & J coccus 1 J & combinatorics 6 ; B cocking E 8 combining site N o D > & cocloning L 2 2M B 2 & commensal J V` & codex alimentarius 0 % comparative analysis @ & ; consensus sequence = & = 2 / B = 2 compensating variation ,# : " . consequence 0 * 6 9 compensation (0 : " & ) ! " management competence factor 0 2 & & B conservation 0 8 / Y $ competency 9 * / 01 ; U conservation of ,/ . 6 Y $ competent authority 9V`N$ J 0 H ; 2 biodiversity competition KN conservation of farm 3 01 C 8 & Y $ competitive exclusion ,# 2 N 6 8 > M & animal genetic resource 0 B & complement G& & conservation tillage 01 YW$ 0 C complement activation G& & H - conservation value 01 YW$ 0 & > complement cascade G& & H @ 2 conserved E , / Y $ complementary G& J & consortia ,# - " + complementary and ,# ; & J ,E H constitutive enzyme ,/ alternative medicine constitutive gene ,/ S , & complementary DNA G& J & constitutive ,/ R & & J complementary medicine ,# ; & J ,E H heterochromatin complementary G& J & ;J constitutive mutation 01 9 $ H nucleotide constitutive promoter ,/ G " & complementary RNA G& J & construct 1 - / P - / 7 compressor H < : consultation 9 - 2 / 9 - & computational biology 01 2 * contact precaution 8+ M 0 H computer assisted new 0 Q # E 2 5 2 contact rate 8+ M 1 " & drug application 9 * contact tracing 8+ M E @ " computer-assisted drug E 2 0 H 2 0 Q J - contact zone K & 6 0 @ H & design contact zone element 8+ 0 @H & 8 B consumption A 2 contact zone thickness 8+ M 0 @ H & 0 J & 2 con-till 0 Y & 0 C contagion 0 2 / T B concatemer H & J 0 ) 0 ; 2 ; 2 contagious 0 @ & 4 &5O 0$8) X " & 0 * 3 % 3 J& (K& (0;2;2 J- contagious disease X " & ! & concentration J contained casualty setting 0 8M D : concomitant 0 8 & 0 contained use & 5 2 configuration E J / 0VI U contained work & & B confined field testing & ,# ; @ Z containment level M T 2 & confocal microscopy 9 _` A * 2 contaminant SG ; & conformation " / J / 0VI U contaminate f H / S 1 congo red & R NJ 0 R 8 contamination S. ; conjugate @ contiguous (contig) map 01 *O 0$8) ,K & & conjugated linoleic acid ; !& = & ( HQ B 0 2 & & conjugated protein = & contiguous gene ,K & & SG & 88 English-Arabic continuous perfusion , & 2 & @ / 91 & 2 & 0 H R critical breed 0 * 0 2 continuous sample 91 & 2 & 0 G B critical micelle 01 R [ - 3 & 2 * J contraindication & " 2M D & concentration 4 control measure ( 1 @ &) H : * critical-maintained breed 9 1 A & 0 0 * 0 2 control sequence ( 1 @ &) H : D and ! @ M controlled release 1 @ & = H endangered-maintained convalescence 0 U @ breed convention B / = $+ crop 8 & convention on biological ,/ . 6 = $+ croplands equipment 01 ;@ # : O 3] diversity cross reaction ,# H; 5 B $ convergent improvement E @ & .2 cross reactivity 01 H; 5 01 ; B $ coordinated framework 3 @+ 3 & ; " =12 & , B H cross tolerance ,# H; 5 .& for regulation of 01 cross-hybridization ,# H; 5 * A biotechnology cross-infection 01 H; 5 T B coordination chemistry 9 Y & J cross-pollination ,# H; 5 F @ ; / ,# H; 5 P copy DNA L 2 & crossing-over 01 C 91 & & * B copy number 0 5 2W > < ;C & & & J ) corn $ 8 9 N% / A& H C # @ @- corn borer 9 W% 6$ ( 8 & 2@ ] & ] corn earworm 9 W% 9 crown gall ,# * . corn rootworm 9 W% % * 9 cruciferae 0; 8$ 3 ) 3 ;8 cornary thrombosis # * HW; * (01 ;8 corona 4 cry protein ,/ 6; coronary heart disease ,# * 6 E ; @ ! & cryogenic storage 9 3 * 7;B 5 correlation coefficient H M & " & 0: $ 5 & corticotropin 01 - > 0 AG* & crystallization ; cortisol 2 & U crystalloid 01 ; 2* / ,# ; cosuppression H C B 2 & cytotoxic 5; $ % counterterrorism E U M , : cultivar 8 / 9 @ country of origin of ,# C 8Q P - & ; cultivated species 0 B G 1A " & genetic resource cultural diversity ,#B . country providing genetic ,# C 8Q ; culture 01 &) 3 2 resource (01 J & covert ,/ G 2 culture medium ,# B 3 2 & / 3 2 H 2 covert release ,/ G 2 = H cultured cell 0 B & 01 ; 5 cowpea mosaic virus W; DW@ K curative ,# * B / X - cowpea trypsin inhibitor W; 2 HG C & curcumin &J J cowpox virus @ ,/ * K curing agent $ - & B creatinine J @ ) J current good 01 D ;G2 D 8 3 2 & & (#;:" manufacturing practices credible threat & UM * / = C & A cutaneous anthrax 01 ; * 0 C 5 9 & * 89 English-Arabic cyanobacteria (9 6 ,#I J 2 >) > cytotoxicity 5 01 G& 2 cyanogen (, 2 <) * 2 cyanosis = D cyanotic ,# > cyclic ,# @ ; daffodil K * cyclic adenosine ,# @; Q 3 $2 / daffodil rice ,# 2 * , monophosphate daidzein .8 ) cyclic amp ,# @; Q 3 $2 / (3 A k , : & cyclic phosphorylation 01 @; 9 $2 daidzen .8 ) cyclodextrin 2J ;J 2 (,# * 2 cycloheximide 3 1 H $ ; , : & ) & 2JU ;J 2 daidzin .8 ) (0& 1& ( H 12; , : & cyclooxygenase ,# @; 2 JP dalton (01 6% 0; NJ 9 ) cyclosporin 2 ;J 2 data 3 & ; " & / 3 cyclosporine 2 ;J 2 data collection 3 D & * cysteine I 2 2 data mining 3 & ; " & B E @ cystic fibrosis 0 C & . ; / ,# 2 NJ . ; daughter 3 cystine 2 2 de novo * & cystitis 0 C & E A de novo sequencing * & 2 ; 2 cyst 0 C & / K NJ de novo synthesis * & = ;5 cytochrome J 2 deafness i H / & 8 cytogenetics 01 ; 5 0 C ; B deagglomeration W J6 D & cytokines 2 2 @ deamidation &Q 0 B & * & cytolysis 5 deamination &Q 0 B & * & cytomegalovirus 5; +5 : & K decay ; cytopathic 5; G& & / 5 B decontamination S. ;6 0 cytoplasm 9 - / 01 ; 5 0 ; * / 2 decontamination kit S. ;6 0 3 C 2 01 ; 5 & ) defective virus (E B ; 5 [ ) Z > K (9 6 defensins G " & ,/ , : & ) $ cytoplasmic DNA ,#& 2 ( cytoplasmic membrane , & - R ) #& 2 - < deficiency Z @ (60 ; 5 & degenerate codon KWJ 9 & / L 2 $ 9 & cytoplasmic vesicle #& 2 * dehydration E6J & & & 0 / $ * cytosine (01 * 9 B >) 2 ,#I & J cytoskeleton # 0J -) ,/ ; 5 J U dehydrogenases * A 0 3 & E Q & J 2 dehydrogenation * A 0 ;5 #H" 0@ >1 H 5 deinococcus radiodurans K KJ J ( A;J- ( J ) cytotoxic 5 , 2 / 5 $ % delaney clause # 9 @ cytotoxic killer 01& 12 5 @ 01 $ & 01 ; 5 deletion * # ) % / 5 / E H - lymphocyte ( # R G8 & 01 C 91 & & 90 English-Arabic deliberate release b H = H dermal penetration ,/ ; * = 5 delivery ; 2 desaturase -M B delta endotoxin ,#; 5 $ % desert hedgehog protein ,/ 8 ,/ % N$ N> demography J.2 0 2 ; B desferroxamine E6J &) & 2J $2 R & denaturation f 2 & / f.2 & manganese I Z 8 &] ,# ;5 & denature f 2 & ( 2* # denatured DNA fG2 & & desulfovibrio & K *) 3 J 0 B & denaturing gradient gel J $ 6 ,# & U ,# A J ( J electrophoresis determinant G & denaturing J $ 6 ,# & U # j A J deterministic analysis ,# & ; polyacrylamide gel [ ; JQ G " & deterministic effect ,# & C P electrophoresis development value . H6 0 & > dendrimer & 0 "- & 9 *- & B) & device 9 ( 8 *Q dextran 2J dendrite 5 3 B. $ 9 G* - & I dextrorotary & ' *+ 01 8 " diabetes / 6J.2 ! & dendritic J6- G $ & / G* - & diacylglycerol 2 ;* 2 # I NC dendritic cell 9 G* - & 01 ; 5 diadzein .8 ) dendritic langerhans cell 9 G* - & U * ] 5 (,# * 2 dendritic polymer G* - & C J & diagnostic procedure ,# 8 5 - * dengue fever virus E J. 71& K dialysis & / ,# I - < 8 / 9 ; denitrification * #I -< denitrifying bacteria * ; 0 ; & J diamond ,K & density 0 C J diastereoisomer ,# > g 8 & density gradient H / 0 C J 4 & % dicer enzyme ,/ 6 !& : U centrifugation 0 C J 4 & ,/ J & dideoxynucleotide * 2JQ Z @ & ; J N dentifrice ,# + 2 * " & 1 & deoxynivalenol * 2JQ Z @ & $ differential display ,/ & ! B (E E 8 ,/ H $ %) differential splicing ,/ & > deoxyribonucleic acid Z @ & ,/ ,/ ! & differentiation = $ / & * 2JQ diffusion - deoxyribonucleotide Z @ & ,/ ; J N digest : A * 2JQ digestion : U deoxyribose * 2JQ Z @ & ,# 2 &N5 6J 2 diglyceride 2 ;* # I C depression ! $ 5 / E VI J dilatation D 2 / D.2 deprotection 0 & 0 dilution $ 5 derepression / E I JM , : & / E I JM 0 dip-pen lithography " & 7;B 01 & ; > 0 B H HG C & 0 dip-pen nanolithography F I - 7;B 01 & ; > 0 B H dermal absorption ,/ ; * Z 8 & 01 J2 J & dermal adsorption ,/ ; * Z 8 & dipel (,/ ,/ - &) dermal contact ,/ ; * 8+ diphtheria antitoxin = N5 $ % , : / = N5 = 91 English-Arabic diploid 3 1 R G8 0 $ B : & / ,# $ " : disulphide bond 3 J # I C 9 8 diploid cell 01 $ " : 01 ; 5 diversity . diplophase ,# $ " : H diversity biotechnology ,/ . + diptheria toxin = N5 $ % consortium direct fluorescent ,D - 2 & , : & 2 * diversity estimation . @ antibody DNA ,/ 6 !& 8 5 &) direct transfer - & @ ( *2JQ Z @ & ,# G direct use value - & &" 2 0 & > DNA analysis ; directed evolution [1* & . H DNA bank 8 & directed mutagenesis [1* & $ H DNA bridges 2 * directed self-assembly [1* & ,# % D & * DNA chimera & 5 directional cloning ,# U * + L 2 2 DNA chip 0 > > directional selection [1* & E 5 / ,# U * + @ DNA diagnosis Z 5 - dirty S1 ; & / f 2 DNA fingerprint 0 & 8 dirty bomb 0 CG ; & 0 ; N> DNA fingerprinting 8 disaccharide # I NC 6J 2 DNA fragmentation - disaster planning 1 U H H 5 DNA glycosylase B > 2 0 disease outbreak ! & #+- $ DNA gyrase disease transmision ! & @ DNA helicase 0 ; * 8 disinfectant GA H & DNA ligase I * H disinfection @ " / A H DNA marker 2 / +; " & disk Z N> / 0 H 2 DNA melting A 8 0 * dispenser G & temperature dispensing D DNA methylase 1 ; C & 0 B & * & 0 : dispersal NC " / C DNA methylation 1 ; C & 0 B & * & 0 : B $ dispersion 9 C " / 3 - DNA microarray & 0 @ > 0 N$ 8 & displacement loop 0 M 0 @ ; / 0 M 0 < DNA polymerase B :6 5 9 & ; disposal Z ; 5 DNA polymorphism J - . " disruptive selection 1 * & @ / =1 & & @ DNA probe ,K * & / 2 & disseminated - & ,# I B WC 5 DNA profiling & D H @ & 0 2 intravascular DNA repair \ 8 coagulation DNA sequence 0 ; 2 ; 2 disseminating C / - DNA sequencing 2 ; 2 dissemination S / - DNA shuffling " disseminator - DNA synthesis D 8 dissimilation WC & KJ B / 0 > H; = ; H & WJ $ DNA typing H & dissociating enzyme 8 DNA vaccine \ @ dissociation 8 $ / = $ DNA vector > distal " DNA-dependent RNA 7;B & " & 9 &; distribution D polymerase disulfide bond 3 J # I C 9 8 dnase W; 92 English-Arabic
DNase W; duplex 4 & (deoxyribonuclease) duplex DNA 4 & docosahexaenoic acid 2J U 2 J !& dura mater (,# < & - < ) 0 * Q - < D - & < G " & ,# U !& ) dust N< ( &12 3 &2Q # * duster $ " 0 docosahexanoic acid 2J U 2 J !& dynafog (0 G : & 0 ) g D - & < G " & ,# U ! & ) dynamics S $ & ) J & ( &12 3 &2Q # * 0 J 2 2*Q 7;B 9 @ C # domain @ / & / * & (0J & domestic animal diversity 0 $ Q 3 . domestic biodiversity ,/ . E domesticate G* / !G / GUV` domesticated species 0$ e. coli 01 8 B J domestication ! early development +J & . H dominant I 2 early gene 9 +J & 0CG & dominant(-acting) I 2 ,# & S G & early protein +J & oncogene earthworm ! Q 9 dominant allele I 2 ecological resilience 01 I 0 & dominant gene I 2 SG & ecological succession (# ) ,# I X donor (#H " &) XH " & / G & ecology 0VI ; B donor junction #H " & 8+ 0 @ H & ecosystem ,# I Y dormancy NJ 2 ecosystem rehabilitation ,# I Y + UP dose 0 B * ecosystem restoration & / ,# I Y+ 2 double helix 4 & ,# ; / 4 & ,# ,# I Y+ double-stranded 0 ; * ,# I NC G& J & ecosystem service ,# I Y+ 0 & 5 complementary DNA ecotourism 01 I 0 2 (dscDNA) ecotoxicology 0VI 01 G& 2 ; B down promoter mutation 0 ;+; @ & G " & 9 $ H ectodermal 01 * 5 9 U Y 01 & 0 @ H down regulating ,# ; $ 2 Y ectromelia +H " DPI 3 B $ 3 9 B > edge effect 06 C drift * / \ edible vaccine JO F 8 \ @ droplet 9 H>c eductor 4 5 2 & drosophila 0 A J $ 0 N% effector +CV` & drought tolerance $ *; G& & efficacy 01 " drought tolerance trait $ * .& 0 $ 8 eicosanoid 2 J drug design & 8 eicosapentaenoic acid !& ) 2 J M !& drug interaction 0 Q NCo 3 # * 3 * & ,# U drug resistance 1 0 & @ & ( &12 drug tolerance 1 .& eicosapentanoic acid !& ) 2 J M !& Duchenne Muscular / - H & 3 : B & : 3 # * 3 * & ,# U Dystrophy - H & ,#; : B C ( &12 93 English-Arabic eicosatetraenoic acid 2 J M !& (,#;5 elastase 2]M +; ,# 2 J endonucleases 01 ; 5 3 ;J electrolyte A J j & / A J endophyte (,#;5 ,# $NH) ,# ; 5 3 electron carrier 3 J M > endoplasmic reticulum 0 & 0J - electron microscopy ,# J A * 2 endorphin electropermeabilization ? 1 I A J %+$ & endosome # #;5 2 *) N;5 electrophoresis ,# A J (# Q 3 electroporation ,# A J a & endosperm H & /%R & a 2 ) 2 electroporesis 0 @6; " & = I >1 ; ,# A J (3 % # * electrostatic , ,# A J endospore ,# ; 5 g elite germplasm * & / 9 & & 01 C 8 & endostatin W ,#" H HG C &) 2 G & & ( O 0 +%R & 01 & 0 B Q ellagic acid * !& endothelial cell 01 H 01 ; 5 ellagic tannin !& &) * endothelial nitric oxide ,# H 2J D+ 8 & ( + 6 synthase embryo 0 R : & / a - & / * endothelin (,#" H 0 B =G ,: &) ; C embryo rescue * % @ endothelium 0 @ > 01 I H 5 embryology 06 *Q ; B endothelium-derived 01 I +H 5 & = - & embryonic stem cell 01 * 01 B % * 5 endotoxic ,# ; 5 , 2 / ,# H , 2 emergency S / e H endotoxin ,# ; 5 $ % / ,# H $ % empirical ,# * engineered antibody ? 1 C K A & , : & 2 * emulsion E ; 2 & engineering 0 2 U enantiomer ,# & g 8 & enhanced nutrition crop ? 1 I % < 12 & 8 & enantiopure g 86 ,# @ enhancement 2 encapsidation W; R enkephalin $J encapsulated ; R enolpiruvil shikimate 3 & J- encephalopathic ,# < &G BM =+; " & enolpyruvil shikimate 3 & J- endangered breed ! @ M 9 1 A & 0 2 enoyl-acyl protein 2 n 5 & endangered-maintained ! @ M 9 1 A & 01 & & 0 2 reductase ( ) breed ensiling ,/ & 5 Y $ endemic H 2 & ! & enterocyte 01 " & 01 ; 5 endergonic reaction 0 > H; ,Z & B $ enterotoxin ,/ " & $ % endocrine gland 1& 8 91 N< entrainment * endocrine hormone 1& 8 91 NR & U environmist 0VI B endocrinology 1& 8 NR ; B environmental etiological ! &; EG 2 & ,# I & B endocytosis @ agent endodermal 01 ; 5 0 @ H environmental factor ,# I & B endoglycosidase 2J ) 2 J ;* environmental fate ,# I 8 & ( J2 3 I * H environmental fate model ,# I 8 & 4 % & endometrium , 1 0 H environmental health 01 I 01 8 endonuclease ,/ ) ,# ; 5 ; J environmental media ,# I H 2 94 English-Arabic environmental media and @ 6 0 1 ,# I H 2 ergotamine (0@ @- 4 " ) & < transport mechanism erwinia caratovora ( J ) J 01 environmental 01 I 0 > & erwinia uredovora ( J ) 01 monitoring erythrocyte & , 5 environmental pathway ,# I 2 & erythropoiesis & 3 1 NJ . J environmental pollutant ,# I S G ; & erythropoietin & 3 1 NJ . J G " & environmental sample 01 I 0 G B eschar ; * W- @ enzootic 3 +H & escherichia coli 01 > 01 J - enzymatic ,# & escherichia coliform 01 > 01 J - enzyme essential amino acid ,# 2 2 ,# & !& enzyme denaturation ,# & f 2 & essential fatty acid ,# 2 2 ,# U ! & enzyme derepression ] HG C & 0 essential nutrient 01 2 2 3 +% R & enzyme immunoassay ,# & 0 B & Z essential polyunsaturated D - & < ,# 2 2 ,# U ! & enzyme inhibitor ,# & HG C & fatty acid enzyme repression 3 J establishment potential K 2P 0 > H enzyme-linked ] =+; " & 0 B & Z estrogen (,/ C & U ) * 2 immunoassay ethanol ,# ; C NJ enzyme-linked = +; " & ,# - 2 ,# B & Z ethical values 01 > 5 > immunosorbent assay ] ethidium bromide 8 $ E6J &) CM & eosinophils ( : 01 & 5) 01 0 H 0 $"G: 1 3 I * epidemic pneumonia 01 I & / 0VIG 3 % 01 I (0 I B epidermal growth factor 9 - , & N & B ethnobiology / 01 3] .2 0 2 ; B epidermal growth factor 9 - , & N & B @ 2 & 01 > B * receptor ethyl acetate C M 3 2 epididymo-orchitis 01 8 5 f E A ethylene ; C epigenetic # & = ;5 =;" & etiological agent ! & & & B epimer ,/ 8 g 8 & etiology ! &Q E 2 ; B epimerase ( ) & eucaryote 9 6 ,# @ @ epiphysitis % 5 $ Y B 0 - - U E A eugenics ? 1 C ,/ - K * .2 episome ( 2 ) ,/ ; B 2 * eukaryote 9 6 ,# @ @ I J epistasis # & =. $ eukaryotic 9 6 ,# @ @ epithelial ,/ A Y / ,# I H eukaryotic cell 9 6 01 @ @ 01 ; 5 epithelial cell 01 I H 5 euploid B B : & 3 1 R G8 B epithelial projection 01 I H 3 8Q epithelium ,# I H - < european corn borer ,# Q 9 W% 6$ epitope , A 2 & * ) 0 & eutrophication 01 %R G * (,#B & " $ evacuation ^ $ epizootic ,# ,# I evaluation @ epsilon toxin ;2 $ % event S equilibrium theory + M 01 Y evolution , H equipment 9 A * ex vivo ,# 2 * 4 5 95 English-Arabic ex-situ conservation J & 4 5 0 & expressivity " ex-situ conservation of , ; J & 4 5 0 & extended spectrum 6H , & & ;2 farm animal genetic ,# ,#C penicillin diversity extension & examination body ,/ 5 & 2 * external cost 01 * 5 0$N; J excipient 1 g 2 extinct ! @ & excision D H > / 8I 2 extinct breed 0 : @ & 0 2 excitation 9 C extinction ! @ excitatory C & extinguisher 0 $H excitatory amino acids C & ,# & !& extracellular 01 ; 5 4 5 exclusion ,# - 2 8 extracellularly 01 ; 5; ,# * 5 chromatography extractive reserve ,#8 5 2 5 & exergonic reaction 0 > H; =;H & B $ external-beam radiation 01 * 5 " - 0 & existence value * 0 & > extranuclear gene 9 6 4 5 SG & exobiology 01 * 5 * extraocular 0 ; @ & 4 5 exocytosis ( A & 0 ;5 %>) K & extremophilic bacteria , H ; 01 & J exogenous ,# * 5 extremozyme 0 " 8 Y 3 &" exoglycosidase ( ) 2 J * 2J exudative RC & I 2 4 5) F : exon 2J (01 I & exonuclease / ) 0 * 5 ;J (#* 5 F exotic germplasm E < SG & exotic species E < facilitated folding 1A 2 & ,# H exotoxin ,# * 5 $ % facultative anaerobe 01 5 01 I U ] expected progeny 26 # 0 "6> & 3 5 facultative cell 01 5 01 ; 5 difference fade gene # & : SG & expiration 0 18 0 A / fall armyworm ( Q L 2 ] ) S " 0 > explosion method * $ M 0 @ H fallow explosive G* $ & false positive E% J E * & exponential growth phase ,# 2 Q , & N H fame * export G 8 familiarity 0 $ exporter G 8 & farnesoid X receptor X 2 @ 2 & exposure !. " farnesyl transferase G& & express G " fat U expressed sequence tag A B 1 " & 0 ; 2; 2 0 & B fatigue A * expression " fats U expression analysis ,/ " ; fatty acid 01 U ! & expression array 01 " 0 $8 & fatty acid methyl ester ,# U !& 2 C & expression library 01 " 0 J & fatty acid synthetase ,# U. !& D+ 8 & expression profiling ,/ " D H @ & fauna 0 @ H & 0 @ 3 expressive dysphasia J "6 0 " 8 fecundity 0 8 N5 96 English-Arabic feedback inhibition 0 " * 0 %R6 H C flavin nucleotide ;J feeder /% R & flavin-linked H & * A feedstock /% R & 5 & dehydrogenase $ fermentation .& 5 flavinoid ferritin ! aI &) flaviviridae & 0 ; 8 ) 9 +$ 8 & 3 2 ( ;* & A (3 2 $ ferrobacteria ; 01 & J flavivirus K *) $18 71& K ferrochelatase 3 +; 5 & 3 & (3 2 $ & ferrodoxin 2J flavonoid fertility 0 8N5 flavonols 3] fertility factor 0 8N5 & B flavoprotein $ 3 fertilization E 8 5 flesh-eating infection W; 0 ; J 0 8 fibrin flora 01 9 fibrinogen $ flourescent dye 01" - & 0 R 8 fibrinolytic agent $; j & B flow =W fibroblast 01 $ 0 & flow cytometry 3 , NJ = , B fibroblast growth factor 01 $ ; 0 & Q , &N & B fluctuant 4G & & fibronectin = 8] ) J fluidized & ( 5; fluidizer D & & field trial 01 ;@ 0 * fluorescence =W P fill O & fluorescence activated ,#@W P 5 B filler epithelial cell 0VI & 01 I H 5 cell sorter filopodia 01 H 5 0 % J * fluorescence in situ 5 1 # ,# @ W P * A filoviridae 3 1 ; $NH & ) / ; hybridization ( @ 9 fluorescence mapping ,#@W P H H 5 filtration F - fluorescence multiplexing ,#@W P B : finger protein +-V` & fluorescence polarization ,#@W P E H@ 2 fingerprinting 01 C 0 & 8 fluorescence resonance ,#@W P 1 0 > H @ firefly luciferase-luciferin n $ 2 ; 0 B Y energy transfer system $ 2 ; fluorogenic probe =+ P & K * & first filial hybrid ,/ 1 * U fluorophore 01 @ W P 018 5 & fitness , J fluoroquinolone J ; flaccid N5 / GU & flux * / =W flagella H 2 flying H flagship species &Q 0 * focal point 01 V` 0 H @N flanking region 01 * 0 @ H & focus group 01 V` 0 B &* & flanking sequence ,# * 2 ; 2 fog E : flavin fogger EG : & flavin adenine ;J ,# I C follicle stimulating 3 * S & U dinucleotide (FAD) hormone flavin mononucleotide ;J ,/ fontan fogger EG : & 8 & 97 English-Arabic food contamination % R S, ; fusion gene 4 & SG & food web 01 I % < 0 J - fusion inhibitor 4 & M D & footprinting @ C fusion protein 4 & M formaldehyde * U fusion toxin 4 & M $ % dehydrogenase U fusogenic agent 01 & 2 * 5 4 & & B formite ! &Q EG 2 & 0; & 9, & futile cycle (3 & ) 01 C B 9 formulation __ J forward mutation 01 &, @ 9 $ H G founder effect b - & CP fragmentation . * g+ 018 5 0$ 8) * E * & frameshift HM ( J frameshift mutation HM ] 0 2 & 9 $H g- 018 5 0$ 8 ) * E 2 free energy 91 0 > H ( J free fatty acid , ,# U !& Gaia hypothesis < 01 : free radical , % * galactomannan 3 U J) & J] * fructan ( J $ CJ& ) J (? C 0 1 " & fructooligosaccharide & 0; ;> 3 J2) 0A J $ 6J 2 galactose J < ( J $ & 9 8> 2 2 gall $18 / 0 8 $ B fructose oligosaccharide & 0; ;> 3 J2) 0A J $ 6J 2 gamete 01 ; 2 01 ; 5 / a - & ( J $ & 9 8> 2 2 γ globulin & * ;< fulminant H 5 γ interferon & * fumarase ( ) & ganglion 0 1 8 B 9 @ B / ,# & K NJ fumaric acid & $ !& garden 0 @ fumonisin (,/ H $ %) 2 & gas < functional food ,#$ Y % < gas exchange 3 R functional genomics ,#$ Y * U gas-liquid #; I 2 / < E - 2 functional group 0 1 $ Y 0 B & * & chromatography functional plan 0 1" 0 HN5 gastric (9 "& Z 5) ,/ " & fungal toxin ,/ H $ % gastrin ,/ " & & U fungicide ,/ H & gated transport ( 1& 8) 0 1 5 & @ fungus H gel U furanocoumarin 0 & J 9 &) & J gel diffusion ,#& U - (3 - ; 9 & gel electrophoresis ,# & U ,# A J furanose (3 J2 & ) gel filtration ,#& U F - furocoumarin 0 G 2 & 01& 2 9 &) & J gem J * / 9 U * ( 2 k a - `. @ d CR; gene * / 0 C G & fusaric acid !& gene amplification 0CG & 5: fusarium 3 H $ & K *) 01 ] R & gene array system 3 CG & E Y (08> gene chip 0 C G & 0 > > Fusarium graminearum E gene cloning 3 CG & L 2 2 fusarium moniliforme $ ; & gene delivery 0 C G & ; 2 98 English-Arabic gene expression 0 C G & " (H; *6 ; D & gene expression analysis 0 C G & " ; genetic assimilation ,#C C & gene expression cascade 0CG & " - genetic code ,# C & gene expression marker 0CG & " 2 genetic disease ,# C ! & gene expression profiling 0CG & " D H @ & genetic distance 0, C 0 2 & gene flow 3 CG & E 2 genetic distancing 0, C 0 2 & gene frequency 3 CG & J genetic diversity ,#C , gene function analysis 0 C G & 0 $ Y ; genetic drift ,#C / ,# C = 2 gene fusion 0CG & 4 & genetic effect ,#C CP gene imprinting 0 C G & 5 genetic engineering 0, C 0 2 U gene insertion 0 C G & 4 genetic erosion ,# C NJo gene linkage 0 C G & H genetic event ,# C S gene machine 0 C G & 0 genetic fingerprinting 0 , C 0 & 8 gene manipulation a " / 3 CG & genetic inheritance 0 * 0C / ,#C S 0B 3 CG & genetic linkage ,#C H gene map 0 * 0 H 5 / 3 CG & 0 H 5 genetic linkage map ,#C H 0H 5 gene mapping 3 CG & H H 5 genetic manipulation ,#C gene modification 3 CG & " genetic map 0, C 0 H 5 gene pool 3 CG & 0 " &* genetic marker ,# C +; " & / ,# C 2 gene probe 0 C G & ,K * & / 0 C G & 2 & genetic material 0, C 91 & gene repair 0 C G & \ 8 / 0 C G & & genetic modification ,#C " gene replacement therapy 3 CG & 2 0 * " & genetic mutation 0, C 9 $ H gene silencing 3 CG & 3 & 8 genetic predisposition ,# C & / ,#" H ,#C N gene splicing $ : / 3 CG & > / 3 CG & genetic probe ,# C ,K * & / ,#C 2 & gene stacking 3 CG & NJ genetic recombination ,#C 4 & gene switching 3 CG & @ genetic resource ,# C 8 & gene targeting 0 C G & A 2 genetic sensitivity 01 C 01 2 2 gene taxi 0 C G & > genetic targeting ,# C A 2 gene therapy 3 CG & 0 * " & genetic testing ,#C Z ُ َ َ ي َ ْ و ُ ّ َ لْ gene transcript 0 C G & f 2 genetically engineered وِ ر ا ِ ّ ً gene translocation / 0CG & D > & R microbial pesticide 0 C G & genetics 0 C ; B gene-bank 3 CG & genistein ) 2 * general release , B = H ( .8 generating genistin ( .8 ) 2 * generation * genitourinary tract ,# ,# ; 2 A * generation time * 3> genome / 01 C & " 0 B &* & generator & # 3 * & * & / generic (0, J; & & <) , B I J genestein 8 ) 2 * genomic library 01 * & 0 J & 99 English-Arabic genomic sciences 01 * & ; B glutathione C ;* genomics * & ; B gluten ;* genosensor ,#C K 2 A * glutenin ;* genotoxic 3 CG &; , 2 glyceraldehyde U 2 ;* genotoxic carcinogen 3 CG &; , 2 H 2 & glycetein 2 * genotype # * H glycine 2 * genus / K * glycine max (#&;B 2 ) geomicrobiology 01 : Q 3 J & 0 G ; B glycinin 2 * germ cell 01 2 * 01 ; 5 glycitein 2 * germ cell gene therapy 01 2 * 5; 01 C 0 * " & glycitin 2 * germ plasm 01 & C * 0; * glycoalkaloid 0 ;> 3 J 2 9 B germinate # - / 3 glycobiology 3 J.2 0 ; B germplasm 0 & C * 0; * glycocalyx # H <) / J 2 J gestation & / ( 5 & " #HR ,/ 6J 2 gestation period & 9 glycoform 7;B / ) J * gibberella ear rot #; * K B $ B (3 U J gibberella zeae ( H ) * glycogen * & / J 2 E J &) * J ;* gibberellin (,# , & N & U ) ; * (3 # gland 91 N< glycolipid 01 6J 2 U globular protein ,/ J glycolysis 3 1 J.2 glomalin (,/ 6J 2 ) & ;* glycoprotein 0 1 6J 2 3 glucagon (K J & U) * J ;* glycoprotein remodeling 01 J.2 3 J - 9 B glucan 9 B & ) J ;* glycosidases 3 1 J.2; 0;; & 3 & (3 1 J.2 glycoside (#I C J 2) 2 J ;* glucocerebrosidase ( ) 2 2 J ;* glycosidic (/ J 2) 2 J ;* glucogenic amino acid J ;*; G J & ,# & !& glycosinolate 3 91 &) 3] 2 J * gluconeogenesis 3 1 J.2 S 2 ( 5 glucose J ;* J 2 glycosylation J ;* H & glucose isomerase J ;* 0< 8 & glycosyltransferase J ;* 0; > glucose oxidase J ;* 9 2J glyphosate 3 2 $ * glucosinolates K 2 J ;* glyphosate & 3 2 $ * F; & glufosinate 3 2 ;* isopropylamine salt gluphosinate 3 2 ;* glyphosate oxidase 3 2 $ * 2JV` & glutamate 3 & ;* glyphosate 32 $ * 5 & 2JV` & glutamate dehydrogenase & * A oxidoreductase 3 & ;* glyphosate-trimesium E6J &) & 3 2 $ * glutamic acid & ;* !& (,/ - &J 5 2 glutamic acid 2J J 0B &*& go gene = ;H & SG & decarboxylase & ;* !& & golden rice ? C 1 " & # U% , glutamine (,# & !& ) & ;* golden rice tm 0J & ? C 1 " & # U% , glutamine synthetase & ;* 0;* 2 & 100 English-Arabic grade 0 * haploid cell 3 1 R 8 01 0 ;5 graft 0"> / "NH haplophase ,# H graft rejection "H6 ! haplotype ,# H & gram molecular weight ,# & < ,# I * haplotype map ,# H & 0H 5 gram stain < 0R 8 hapmap ,/ - ,/ Q * & 0H 5 gram-negative R ,# ; 2 hapten 0 - gram-positive R ,# * haptoglobin ;* U granulation tissue # a 2 hardening 0 2 @ granulocidin [* ) 2 * harpin (/ J ) U ( : 5 harvesting 8 granulocyte 0 1 & 0 ;5 harvesting enzyme 8 granulocyte colony 5 3 &" 2 & +$ & & B hazard H 5 & stimulating factor 0 1 & hazardous substance 9 H 5 9, & granuloma # health hazard 01 G8 7;B H 5 green fluorescent protein : 5Q ; =+ P & heat-shock protein 01 0 & 18 green leafy volatile :5 = Q H & heavy-chain variable 0 ; @C 0 ; 2; 2 3 5 greenleaf technologies :5Q = 3 @ hedgehog protein %N$ N@ growth , & N hela cell 01 H 2 5 growth curve , & N 7 & helicase ( ) J ;U growth factor , & N & B helicoverpa zea ( NHN@ ) 9 W% 9 growth hormone , & N & U helix ,# ; growth phase , & N 0 ; & helper T cell 9 B 2 & T 01 ; 5 guanine (0 * 9 B >) * hemagglutinin & 1 3 , NJ ,Z guanylate 3 ; * hematochezia # & & H. R guanylate cyclase 3 ; * =+; & hematocrit & 1 3 , NJ 0 2 guild (3 8 # ) 0$I H hematogenous P - & ,/ & gun hematologic growth 1 3 , : B , & N & B gyrase ( ) * factor hematopietic growth 1 G J & , & N & B H factor hematopoietic stem cell 01 & 01 B% * 01 ; 5 G J & habitat H & heme B P- ^ 8) & U habitat restoration H & & ( ;* & A hairpin loop "- K 0@; hemoglobin E : 5 / & / ;* & U hallucination 02 ; U halophile F; & hemolysin 01 & 0 hand hemophilia 1 ! & hand-held ? & & / ,/ hemorrhagic mediastinitis ,#H 2 hantavirus U K hemorrhagic pleural ,# * ,# E 8 hap gene S SG & effusion haploid 3 1 R 8 ,/ hemostasis (,/ & > ) > 101 English-Arabic hemostatic derangement ,#I > ; 5 high-throughput (9 $J) 0 B 01 * % heparin H; * ; D & identification hepatatrophic J & : high-throughput 9 $J % 0 B 01 * % h hepatorenal syndrome 01 ;J 01 J 0 & & screening 0 B herbicide E -B & highly available 9 J 3 1 &J * & $2 herbicide resistance E -BQ 3 & @ & phosphorous herbicide-resistant crop E -BQ 3 & @ & 8 & highly unsaturated fatty 9 J 0 * D - & # & ! & herbicide-tolerant crop 3 & G& & 8 & acid E -BQ hilar adenopathy @ 9 .2 B heredity 0C hirudin ( C56 ; , : & ) U heritability S histamine # $ 0 :B 9 B >) & 2U hetero- n ,/ < / n ; 5 & / n R & # E 2 A 8 B 0*2 ] heterochromatin R & & J / R & R 8 (0 & 0 B Q D 2 heterocyclic 0@; R & histidine 2U heterodimer R & ,/ C & histiocyte 01 * 2 01 ; 5 heteroduplex R & B : & histoblast 0 * 2 01 NJ heterogeneity 01 R histocompatibility ,#* 2 =N heterogeneous K * & < / P - & R & histone H 2 / ,/ B > heterogeneous nuclear P - & R & ,/ histones 0H 2 3 RNA histopathologic ,#* 2 ! & heterokaryon T 6 9 R & HIV / - #B & " K heterologous E < / ,/ < / P - & ,# * holin U (,/ 2 < D: & # a 2 ) hollow fiber separation 0 1 * & Q 8 heterologous DNA P - & ,# * ,/ holoenzyme & ,# $ Y * / ] & heterologous protein P - & ,# * ] heterology 01 R / K *Q 5 ; B homeobox 2; 2 [ - & 8> heterosis 0 8N5 ) : O R homeostasis ,# % ( * A " homing receptor [1* & @ 2 & heterotroph /+% R6 ,/ < homocysteine 2 2 & U heterotrophic /+% R6 ,/ < homogeneous K * & heterozygosity (0 > ) 3 * R homologous = H & / C & & heterozygote (0 > ] ) I]Q 9 R & 3 * homologous chromosome 0; C & & 0, C 3 +R 8 hexadecyltrimethylammo & C & / J 2JU homologous protein 0; C & & 3 nium bromide & homologous C & & E -P hexose #2 2 J 2 recombination high blood pressure D$ & HR : homologue gene / Y SG & / C & & SG & high-content screening # " T &; h SG & high-density lipoprotein 0 CJ # B ,#& - homology / C & high-efficiency 01 "$ 018 5 U 0 $ 8 0& 1& J homology modeling = 2 [ - particulate air filter 0 B homotropic enzyme ,#I 2 C & & mask homozygote (0 >]) I]Q 0; C & & 3 * 102 English-Arabic homozygous I]VQ 0 ; C & & 3 * =+; " & hybrid * U (0 >]) hybrid vigor * A 91 N> horizontal disease ,#@ Q ! & @ hybrid zone * A = H transmision hybridization * A hormone & U hybridization surface # * A F H 2 hormone response 0 & U 0 * 2 8 B hybridoma * U element hydration `. & / [. & horseradish peroxidase 5 * 3 # 9 2JQ hydrazine U hose H N5 hydrazinolysis 5 2 &Q H 2J hospital information 7$- 2 & 3 & ;" & Y U system hydrofluoric acid ;$ ! & H - host : & / I B cleavage host cell I B 01 ; 5 hydrogen * A 8 B host factor I B 8 B hydrogen bond 0 * U 0H host vector I " > hydrogen sulfide * A J hot spot 0 5 2 0 "@ hydrogenation 0 * U human artificial 01 B 8 2 3 1 R 8 hydrolysis (#I & ; ) 0 A & ; chromosome (,# B H 8 # 2 2 & J) hydrolytic cleavage # A & ; H - human embryonic stem 01 * 0, B% * 2 0 ;5 hydrolyze [ & ; cell hydrophilic &; ,E & human equivalent 2 k b J & J hydrophobic & ; ,E & < concentration hydroxylation reaction 0B &*& 0 : B $ human genome project 2 k 01 C 91 & - & 2J A human growth hormone # 2 M , & N & U hyperacute rejection 91 - ! human / - #B & " K hypercholesterolemia 2 J H immunodeficiency virus hyperchromicity 01 R 8 9 human leukocyte : 1 3 , NJ 3 , : 2 & hyperimmune 0B & H $ & antigens 0, - hypernatremia 8 H human superoxide 2J 2 &2 hypersensitive response K.2 H $ 0 * 2 dismutase / - hypersensitivity K.2 H human 01 > , 91 NR; +$ & / - & U hyperthermophilic H $ & 9 ,E thyroid-stimulating hypoglycemia J 2 Z @ hormone hypostasis CP # R; SG & / 1 J humanized antibody 0 , - 3 1 : 2 & 5p humidifier E+H & hypothalamus (g &G # ) / 8 A & 3 humoral immune 01 H; 5 01 B & 0 * 2 hypoxia a 2 JP Z @ response humoral immunity 01 H; 5 0 B & I humoral-mediated H ; 5 0H2 0 B & immunity ideal protein concept # C & A$ & Huntington's disease * U ! & idiotope D : & / # % H & / J & 103 English-Arabic
# % /, : importer 2 & inhalation = - 2 imprinting D 6H W; " intercellular adhesion 5 & = 8 ; & e * in-silico E 2 5 molecule in-silico biology E 2 5 2 9 ; B illegal traffic < 9 * / 01 > < 0 J in-silico screening E 2 5 2 F 2 & 01 > in-situ 5 1 # / [ " : & # imidazole & in-situ condition ([ 2 $ J & ) 5 1 NY immobilization j - / @ 2 / [ J& # ' G& * in-situ conservation [ 2 $ J & # 0 & immortalizing oncogene ; 5 & #& * in-situ conservation of 3 # C . 0 & immune function 01 B & 0 $ Y farm animal genetic J & K $ # 0 B & immune response 01 B & 0 * 2 diversity immune sera 01 B & 8 & in-situ gene bank J & K $ # 3 CG & immune system 0B & A * in-vitro ,# I J 4 5 / E Q # immunity 0 B & 5 & # / immuno-enhancing ,#B & " in-vitro culture 4 * E 5 0B immunoadhesin 0B & in-vitro evolution 4 * E 5 . H immunoassay 01 B & 0 2 @ & in-vitro selection 4 * E 5 @ immunocompetent ? , B & ,U V` & in-vivo Q # / ,# 2 * # immunocompromised 0B & Z @ & inbreeding E >Q 4 / ,#; 5 4 immunocompromised 0B & Z @ & I B inbreeding depression / E >Q 4 ! $ 5 host ,#; 5 4 ! $ 5 immunoconjugate 0B & > incapacitate " : immunocontraception & D & 0 B & incapacitating agent " : & & B immunodeficiency ,#B & B / ,#B & Z @ incapacitation 7;B 9 N@ 91 @ H B / * B immunodominant ? B & I 2 F 2 J / & " immunofluorescence ,#B & =W P incidence > / S immunogen : 2 & / D & 2 & incidence rate > 1 " & immunogenic D & 2 & inclusion body & - & 2 * immunoglobulin & 0B &*&) ,# B & ;< income N5 & 2* # ;* 3 incomplete dominance 0 ; & J < 9 2 (,/ , : &J &" incubation 0 : immunologic ,# B & incubation period 0 : 9 immunomagnetic 0 G2 H R & 0 B & indicator species 0 $ - J immunosensor 01 B & 0,2 indirect contact - & < 8 immunosuppressive 0 B & Y & 5 / 0 B & 3 J indirect source < E 2 / - & < 8 & immunosuppressive 0 B & Y & 5s 0 * " & - & therapy indirect transmission - & < @ immunotherapy 01 B & 0 * " & individual risk ,/ H 5 immunotoxin ,#B & $ % induced fit S 2 & c` / !1 & c` implant radiation "NH " - inducer S & / !G & import 2 inducible enzyme !G & 104 English-Arabic inducible promoter ! 6 ; > " & insidious < / J & / 5 & induction S / ! insitu ,# " H [ J & # induration EW;,8 / 0 2 @ / 9 2 * insulin 2 infarction - insurance value &P 0& > infectibility T " 01 ; > intake 5 & / % 5 infection T B intake rate % 5Q 1 " & infectious ,# I B / (/ " &) XX " & integrated crop 0; & J & 8 & 9 infectious aerosol X " & E : management infectious agent X " & & B integrated disease 0; & J & ! &Q 0 J & infectious disease X " & ! & management infectiousness B integrated pest 0; & J & 3 p 0 J & infective ,# I B / (/ " &) XX " & management infectivity T " 7;B 9 N@ / B integrin * infestation - / 3 1 ; $WH T B intein infiltrate F+- intended release 8 @ & = H infiltration \ - / F - interferon information exchange 3 & ; " & interferon-β information RNA ,# & BM intergenerational equity *Q & 9 2 & informational molecule ,# & ; " & e * intergenic region 3 * 0@ H & ingestion A / interleukin J inhalation = - 2 intermediary metabolism HG2 & E @ 2 inhalation exposure = - 2 k ! . " internal radiation ,#; 5 "- inhaler 0 @ - & internaulin inhibition H C intoxication J 2 / .& 2 initiation intracellular 5 5 / ,/ ; 5 & : initiation codon 01 I 9 & intracellular membrane ,/ ; 5 & : - < initiation factor M & B intracellular transport ,/ ; 5 & : @ injector 0 @ & intradermal ,/ - / ,# & / 0 & Q 5 innate immune response (01 <) 0 1 H 0 1 B & 0 * 2 intravenous antibiotic ,/ ,/ : & innate immune system (1/ <) ,/ H ,# B & Y intravenous therapy ,/ @ 0 * " & innocuousness & / : B intrinsic protein P - & ,#; 5 inoculum 0 @ introduced species 5 & inositol 2 introduction 5 / 0 &G @ & inositol lipid ,# U 2 introgression 3 CG & 5 / ,#; 5 * inorganic ,/ : B < / ,/ : B ] intron insect 9 - inulin (# - ) insect cell culture 3 - 5 0 B invasin ( ) $ insecticide ,/ - & invasive j ,# B / / < insertion mutation 0 ; 5 & 9 $ H invasive species ,# B insertional knockout 5 M 3 & Y invasiveness (0 <) R 7;B 9 @ & system inventorying DI : 5 & * 105 English-Arabic inversion % %N- / E @ joining (J) segment J J- 7;B 3 - inverted micelle 2 * :0 ; % &) 0 ;@ & 0 ; % & jumping gene 9 > 0CG & (0 < [ - 9 & # E A J & juncea 5 / E J investigational new drug * B 8 @ 2 Junk DNA J # B < investigational new drug 0@ H 0 C 3 * " 5 2 treatment 01 I 8@ 2 K ion ion channel Q 9 > kanamycin (,/ , : & ) 2 & J ion trap Q 9 8 & kanr 2 & J; : & SG & ion-channel-binding toxin 3 Q 9 @ H & $ % karnal bunt 0 H E 8 ! & ion-exchange 3 Q E - 2 karyotype ,/ H & chromatography karyotyper ,/ HG& & ionization . P kb # H K > 9 ) 9 B > ; J ionizing 3 Q 8 1000 / 2 01 I * * ionotropic # (0 * 9 B > iron bacteria J kefauver rule $ J > iron deficiency anemia B B a , @ keratin 0 * 2 ] # 3 ) J irradiation "- / D " - (0 G @ & irritability 01 * A ketose / H 2 / J 2) J isoenzyme #& Y < # J 0B &*& 7;B isoflavin (0 H 0 A isoflavone ( $ C & &) keystone species J & isoflavonoid killer t cell @ t 0 ;5 isolation B kilobase 9 ;J / 9 B > ; J isoleucine 2 kilobase pair 9 B > 4 ; J isomer g 8 & kilodalton K @ 9 ) ; J isomerase 0 < 8 & ( 1000 / 2 isoprene kinases 0 : 7;B &" ) J isotachophoresis 0 B 2 = 26 & ([ J 7 0 $2 0B &*& isothiocyanates 3 2 C kinesin 2 J isotope Y kinetic ,# J isozyme #& Y kinome 3 9 $2 0 ;&B) J itching 06J ( J 5 2 knapsack AY 0 @ J knockdown 0 : > 0 : knockin = H jasmonate cascade & 0 ; 2; 2) 3 & * 6 - knockout 0 B 8 0 : B ; 0 3 B $ knottin (9 @B % F 8 ) @ B ([2$ konzo (! & 2 ) J jasmonic acid &2 * ! & koseisho , 1 Y 0 0 J jimson weed 2 & * 0 - B ( - J) 106 English-Arabic kozak sequence K&5 & 0 J&) J 0 ; 2; 2 leader sequence I @ 2; 2 9 & > D@ 3 ;J leaky mutant (0 2) 0 - 9 $H (0 lecithin (! $ 8) C 2 krebs cycle ! & 9 ) K J 9 lectin J (0 C C legume ( @ ) 3 1 @ kunitz trypsin inhibitor 2 HG C & J leishmaniasis 3 1 & - +; leptin L leptin receptor @ 2 & lethal 3 & & label 2 / 2 6 0> 8N lethal concentration 3 & & J labeled 2 & lethal mutation 0 & & 9 $ H labile G R & lethal toxin 3 & & $ % lac operon ] +R - & leucine 2 laccase ( ) J] leukocyte : 0, NJ lachrymal fluid ,#" & I 2 leukotriene (,/ > E A H 2 ) J lactic dehydrogenase J * U 0 B level T 2 & lactoferricin 2 J] levorotary 6 ./ 2 V lactoferrin J] liability 01 ` 2 & lactonase ( ) J] liaison 0@ C 0 ; 8 / 0 & 0 > B lactoperoxidase ( ) 2J J] library 0 J & lag phase `WJ ;6 H lifetime (9 HG2 &) & B lambda bacteriophage &] J A ; & ligand ( 5 e * ; e *) * lambda phage &] >] ligand-activated * 0H2 6$ f 2 & B landrace 0 1 ; & 0 2 transcription factor langerhans cell (0 B & / @N ) U * ] 01 ; 5 ligase (H ) R ] laser capture ; E > & ,/ A * & f ; 2 ligate H microdissection ligation H laser inactivation ; 0 " $ H" light-chain variable 0$ $5 0 ; 2; 2 3 5 late effect +5 P & C P lignan R late gene +5P & SG & lignin a 2 # 01 : B 91 &) R late protein +5P & (3 ; # -5 latency &NJ / $ 5 lignocellulose # - 5 ;; 2 latency period &NJ 9 limonene & lathyrism 1 N; * .& 2 line-source H 5 8 & laurate (0 U ! & Q ) 3 line-source delivery H 5 8 & 8 Y & lauric acid ! & Q ) ; !& system (0 U lineage 0 G N% / 0 2 lawn 0$ - & / i - / 4 & linear energy transfer 0> H / ,#H 5 0> H @ lazaroid 0* "& &" 2 EJ &) ,# H 5 (! &] !" linkage H leader I > linkage group H 0 B & * & 107 English-Arabic linkage map H 0H 5 standoff detection T & H linked gene/marker 0H & 3 CG & 2 system linker H / 8 & lopopolysaccharide ,# U. 3 J 2 B linking H loss-of-function mutation " $ @N 9 $ H linoleic acid ; !& low calcium response 2 J; 0 * 2M ;@ & linolenic acid ; !& plasmid lipase ( ) ] low-density lipoprotein 0 CJ ;> # U lipid - / U luciferase $ 2 lipid bilayer 0 U. 3 @ H #I NC luciferin $ 2 lipid raft 01 U E * / ,# U D.& * lumen N0 1 . N9 ) / 0 " & lipid sensor 01 U 3 12 * & (,# I G: ! $ ; lipid vesicle 01 U 0 ; 8 / ,# U * luminesce " & lipidomics W- ; B luminescence =W P lipolytic enzyme 3 U. ; j luminescent assay 01 @W P 0 2 @ & lipophilic U. ; E & / U. ; luminophore & ; & lipopolysaccharide B / 01 U 3 U J lupus (/ ;* ) 0 I+% ,# U. 3 J 2 lupus erythematosus 0 & &5 0 I% lipoprotein ,# U lutein lipoprotein-associated 01 U. 3 H & WC 5 luteinizing hormone ; & & U coagulation luteolin $ 8 2 * liposome ,# U 2 * lux gene lux S & lipoxidase ( ) # U 2J lux protein lux lipoxygenase +$ ) # U * 2J lycopene J < 0 U. ! & Q 9 2J lymphadenitis 01 $ &+; @ " E A (0 " - & lymphatic endothelium 01 $ &+; E ; @ 0 H lipoxygenase null 9 I $ B # U * 2J lymphocyte 01 $ & + liquid I 2 lymphocytic 12 E A K listeria monocytogene & K *) * 2 & 01 2 choriomeningitis virus / $ & +; 3 & -& ( J lymphocytosis 3 1 & +; 9 C J live cell array 01 01 ;5 0 & Y & lymphogranuloma ,#$ & # live vaccine strain ,# \ @; 0 2 lymphokine J $& liver J lyochrome ( ) J living modified organism 12 & # I J lyophilization ( & *6 $* ) $ * localized ,# " : & lyse j V locomotion . lysine locus D : & lysis log growth phase # & < ; , & N H lysogen E % 2 & log phase #& < H lysogenic E % 2 & logarithmic phase #& < H lysogeny 0 % 2 London Fog Foggers E : iG - lysophosphatidylethanol C M 3 & $2 long-range biological Y+$ & #* - J Y amine 108 English-Arabic lysosome ; marker 2 / +; " & / 0 & 8 lysozyme marker-assisted breeding 01 C 3 & 2 9 B 2 & 0 lytic W; M =+;" & marker-assisted selection 3 & 2 9 B 2 & E 5 lytic infection 01 0 8 01 C marple aerosol generator & E : + & M mask > mass screening & - F 2 & machine 0 J & / 0 mass spectrometer / ; J 6H K @ & macrolide ,/ , : & ) J & mass-applied genomics & - #@ H 3 CG & ;B (,/ J & mass-casualty biological 0J 6 01 0 ;2 macromolecule 5 : e * weapon macrophage " ; massively parallel 5 : / & 9 - 2 ; 2 macrophage activiation B H - signature sequencing macule 0 " @ mast cell / C 0 ; 5 / 0 & 8 & 0 ;5 & -maculopapular 01 C 0 5 H / ّ ِ َ ّ ِ ْ ُ matrix metalloproteinase ( ) #J mad cow disease @ * ! & maximum contaminant S. ; T 2 & 7;B magainin * & level magic bullet 01 2 08 8 maximum permissible [ \ & 2 & J 78> magnesium sulfate 2 R & 3 J concentration magnetic antibody ,# 2 H R & , : & 2 * maximum residue level 3 @ & T 2 & 7;B magnetic bead 01 2 H R & 3 maximum sustainable 2 & 4 7;B magnetic cell sorting ? 1 2 H R & 5 8 yield magnetic labeling ,#2 H R & 2 maysin 2 & magnetic particle 01 2 H R & 3 I * mean lifetime 9 & B HG2 & maillard reaction & B $ medical control #G H WJ major histocompatibility J G# * 26 =N 6 6@ " & medical informatics #G H 3 & ;" & ; B complex medifoods HG2 & " H male-sterile ,/ J % @ B mediterranean fruit fly HG2 & ! Q 0 N% malformation '. - medium 3 2 & / H 2 malignant S 5 medium chain saturated 0 ; 2 ; 2 0HG2 & 0 " - & U malignant edema 0C 5 0 &% fats malnutrition 0 %R6 2 medium chain 01 C NC 2;* 2 0 ; 2 ; 2 mammalian cell culture 3 1 G C 5 0 B triacyglyceride 0HG2 & mandrake root (\ $ N; ) \ % * medium chain 0 ; 2; 2 0HG2 & 0 C NC U mannan (0 J 2 9 &) & triglyceride mannan oligosaccharide & 3 J 2 ;> medium intake rate HG2 & % 5 1 " & mannogalactan (01 R & 8 9 &) J] * & mega-yeast artificial ,#B H8 5 : 9 & 5 ,#R 8 map distance 01 H 5 0 2 & chromosome mapping # 3 CG &; ) 0 " : & megabase 9 B > ; & (3 1 R 8 megabase cloning 5 : L 2 2 marine toxin / .&2 megakaryocyte 1 6 +$ & & B 109 English-Arabic
stimulating factor meiosis 8 / ,# 5 ,/ ; 5 2 @ metabonomic signature & & 9 - melanoidin (01 9 &) & metabonomics K @ & 02 ; B) KJ & & melting ( A 8) A 8 3 ;&"; 01 G& J 0 * 2M melting temperature A 8 M 0 * (0 : I & membrane - < metalloenzyme ,/ ; membrane channel - R 9 > metalloprotein ,/ ; membrane filtration F - / - R 0 H 2 9 ; metallothionein ,/ ; C ,# I - < metamodel ,#: 4 % & membrane transport ,#I - < @ metanomics &* & 02 ; B) KJ& & membrane transporter > ,#I - < (,# I J # 0 : I & 3 ;&" protein metaphase ,#H 2 H / ,#I 2 H mendelian transmission # & @ metastasis 0 ; @ menopause K P , 2 / K meteorology 01 G * 8 Q ; B mentation ,# ; @ B H - meter & mercury = _I metered K @ & mercury knapsack ,#@ _I ,# : ,/ A Y i & metering 9 " & mistblower methanol C & mesenchymal adult stem 0 & W; 0 R 01 B % * 01 ; 5 methionine C & cell 0 HG2 & methyl jasmonate 3 &2 * C & mesenchymal stem cell 0 HG2 & 0 & W; 01 B % * 01 ; 5 methyl salicylate 3 ; 2 2 C & mesodermal adult stem HG2 & O 0 R 01 B % * 0 1 ; 5 methylated ( C & [ : &) C & & cell micro sensor = > ,K * & mesophile 0 " & 9 V micro total analysis ,#;NJ ; 6 ; = > Y mesoscale ,#H 2 a system messenger RNA 2 & micro total analytical = > ,#;NJ ,#; ; Y messenger tm 0;1* 2 & 0 J & 2 & system metabolic disturbance 01 : 3 H : micro-electromechanical = > ,#J J & ,#I A J Y metabolic engineering 01 : 0 2 U system metabolic flux analysis ! Q =W ; micro-organism = > I J / ,/ A * & ,# I J metabolic pathway 2 & / ! Q 3 B $ 0 ; 2 ; 2 micro-RNAs = >1 n ! Q microaerophile ;@ A metabolic product ! Q 4 microarray 0 @ > 0 $ 8 & metabolism ,# @ 2 ( U ) ! microbalance = > & metabolite 0 : / 0 : I & / E ; @ 2 & microbe E J & metabolite profiling ! Q a ! " 2 microbial mat 01 J & 9 8 metabolome 0 : I & & &* &) & microbial physiology 3 J & I Y ; B (,# I J microbial source tracking 3 J & 8 & EW@ " metabolomics & 0 2 ; B ) KJ & & microbicide 3 J & & (,# I J 0 : I & microbiology Q ; B / 0 @ > metabolon 0 ; 8 & 0 : I & & 0J - * J & / 01 A * & 110 English-Arabic microchannel fluidic 9 @ 0 @ > 01 A * & I 2 9 A * mitigation 6$ 5 / 6J 2 device mitochondria 3 1 2 / 3 G @ & microenvironment 0 J & 0VI / 0 @ > 0VI mitochondrial DNA ,/ G @ & microfilament 0 @ > H N5 mitogen 2 @ k S & / W $ ; S & microfluidic chip 01 A * & I 2 = I > ,#; $ microfluidics 01 A * & I 2 mitogen-activated protein +$ & J - microgram < J & kinase cascade ,#; $ 2 @ k microinjection # J & @ / = > @ mitogen-activated protein 2 @ k +$ & J micromachining 0@ > 01 kinases ,#; $ micromodification = > " mitosis 2 @ / W $ / ,#; 2 @ micron (K > 9 ) J & - & micronair (0 - & 2 ) J & mixed-function I Y G " & 2 JV` & micronair AU4000 AU 4000 J & oxygenase micronair spray nozzle 01 J & 01 % % 0 U1 N mixing H ; 5 / 4 & microorganism = > ,# I J / E J & model organism 4 % & ,# I J microparticle = > 2 * modeling 0 * % & / g 8 microphage " ; modifying factor G " & & B / G & & B micropropagation = > C J moiety 18 T / 8 / * microsatellite DNA # J & D 6 2 & microscopy ,/ A * & Z / A * 2 mold /َ24 / $ B microsphere 01 J & 9 NJ mole / (# & R #I * ) & microsystems technology 0, A * & 0 & Y Q 01 + @ (# & 0 ; NJ ) 7 microtubule E c / 0@ > 3 c molecular beacon ,# I * - & / ,# I * b : & microwave bombardment 01 $ J & 01" -Q % > molecular biology 01 I * * mid-oleic sunflower 3 1 01 B 12 & K &6- 1 B molecular breeding tm 0;1* 2 & 0 & B 01 I * 0 mid-oleic vegetable oil 3 1 01 B 12 & # 3 molecular bridge ,# I * 2 * mild effect $ 5 CP molecular chaperone ,#I * . H milled H & molecular cloning ,#I * L 2 2 milling 2 / H molecular diversity ,#I * . mimetics 9 J & molecular evolution #I * . H mini 7 / R 8 molecular fingerprinting 01 I * 0 & 8 minimal risk level 7 Q 0 * & T 2 & molecular genetics 01 I * 0 C minimized domain j R 8 & * & / !6$ 5 & & molecular lithography 0 1 I * 0 1 * 0 B H minimized protein !6$ 5 & molecular machine 01 I * 0 minimum tillage 7 0 C molecular mass 01 I * 0 ; NJ miniprotein R 8 molecular pharming tm 0;1* 2 & 0 & B 01 I * 0 B miniprotein domain R18 * & molecular profiling ,#I * 2 minute volume ? 1 * R 8 * molecular sieve ,# I * N5 & mismatch repair b H 5 4 \ 8 molecular vehicle ,# I * > / ,#I * g 2 mist = > E : molecular weight ,#I * mist blower (E : 0 % > ) i 6- monarch butterfly 0 & 5 : 0 - 111 English-Arabic monkeypox 9 @ 1/ * / K 2 + ./ * multiple aleurone layer 0 @ H G " & 0CG & monoclonal 0 ; G2 ,/ gene monoclonal antibodies 0 ; G2 01 91 : & 2 * multiple sclerosis G " & EW; 8 monoculture ,/ 2 multiplex assay 9 G " & 0 2 @ & monocyte 3 1 NJ & ) 9 multiplexed B : & / G " & ( : multipotent 3 N@ G " & monoecious J 2 & ,/ multipotent adult stem 9 G " & 0 R 01 B % * 5 monogenic SG & ,/ cell 3 N@ monogenic disorder / SG & ,/ E H : multivalent `N J6 G " & # & E H : munition E B / I 5 % monomer & murine ,/ P mononuclear 9 6 9 mutagen +$ H & mononuclear cell 9 6 9 01 ; 5 mutagenesis / $ H monosaccharide / J 2 mutagenic compound +$ H & E6J & H / $ H 2 $01 / ََ ل monounsaturated fat 0 " - & < 01 U mutagenicity monounsaturated fatty 0 " - & < 01 01 U ! & mutant 9 H acid mutase ( ) & morbidity ! & / 0 : & mutate +$ H / G moribund : & mutation 9 $ H morphogenetic =+; 5 & mutation breeding 3 $ 6H 2 / 3 $6H 0 morphology ,# ; J 6- E J 6 ; B mutualism DN mos ,# 2 SG & 2 ) K & mycobacterium 01 +; 2 9 +H $ & ( G & tuberculosis mosquito ! " mycorrhizae (0 " 3 1 H ) J & motor protein (,# J ) G & mycotoxin ,/ H $ % mounted 7 2 & myelitis 5N E A / Y " # @ E A mouse-ear cress [ - 3 2 ) 2 ,# J 6- ( -1 myeloma ,/ @ movable genetic element ( +@ &) G & ,#C 8 B myocardium ,# ; > ,# ; : B mucoid H 5 & [ - myoelectric signal 01 ; : B 0 I A J 9 - mucous membrane 01 H 5 & 0 < / ,# H 5 & - < myristoylation 0 ;&B) - ; 2 & multi-agent munition & " 9 G " & I 5 % (3 ; 0 * 0 A multi-copy plasmid f 2N G " & & myrothecium verrucaria ( H 2 ) J 2 C & multi-drug resistance 0 0 B & * & @ & multi-layered 01 " # B 3 @ H G " & > N high-efficiency A 0 @ particulate air mask nadir ,# : : / $ 2 / Y multi-locus probe D > & G " & 2 & naïve T cell 0 H 2 T 5 multienzyme system 3 & ] G " & Y naked DNA 1 * & multifactorial disease & " G " & ! & naked gene X B 1 * & SG & multigenic 3 CG & 9 B nanobiology ( ; & & *) 01 01 112 English-Arabic nanobot = > E necrotizing lymphadenitis @ 01 $ &+; @ " E A nanocochleate ,/ ,# ; needs assessment 3 * @ nanocomposite ,/ E J neem tree + 9 * - nanocrystal 01 9 6; negative control 01 ; 2 9 H 2 nanocrystal molecule ,/ ,/ 6; e * negative supercoiling ,# ; 2 $ nanofluidics 01 I 2 nematode / 9 1 & 9 / 9 2 & & 9 9 nanogram ( < 10) < & nanolithography 01 01 * 0 B H neoantigen S 2 & , : 2 & nanometer K > 9 / & A * neoendemics H 2 & S ! & nanoparticle ,/ 2 * neoplasia `W- / . J nanopore ,/ E @NC neoplasm nanopore detection ,/ E @NC B - J neoplastic growth ,# & , & N nanoscience ,/ ; B nerve growth factor E 8 " , & N & B nanoshell 01 9 - > net present value 01 8 01 0 & > nanotechnology 01 3 VI * * J neural ,# 8 B nanotube ,/ E neuraminidase ( ) & N nanotube membrane ,/ E - < neurologic sequelae 01 8 B @ B nanowire ,/ ; 2 neuron 01 8 B 0 1 ; 5 / 8 B napole gene 0CG & neuropsychiatric ,# 8 B ,# 2 $ ,E H narcosis . 5 neurotoxin ,# 8 B , 2 naringen (,/ ) * neurotransmitter ,# 8 B > nark gene KG2 * & SG & neutraceuticals 01 $ Y 01 I % < 3 : 2 & nasopharynx ,# $ VQ * ) ,# $ V " ; neutriceuticals 01 G 8 01 I % < 3 : 2 & ( " ; ; neutropenic 0 " & 0@ > H N5 native conformation ,# +; & J neutrophil 0 B native species 01 +; & neutrophils 3 ] B native structure ,# +; & J U new animal drug 9 * 01 0 & " 2 naturaceutical 01 " H 3 : 2 & application natural forest 01 " H 0 < new drug application * 1 & " 2 natural immunity 01 " H 0 B & niche i B natural killer ,#" H > nick 0 B 8 natural killer cell 01 " H 0 ; > 01 ; 5 nick translation 0 B 8 0 & * natural selection ,# " H E 5 nicked circle # ; 2 ; 2 T ) 01 B 8 0 @ ; natural source ,#" H 8 & ([8 5 2 5 0 B 8 & near-infrared 3 0 1" - Q ,# $ H Y ninhydrin reaction - J ) A B $ spectroscopy & (3 near-infrared & 3 01" -Q @ nisin (,/ , : & ) 2 transmission nitrate 3 nebulizer 9 % % nitrate bacteria 3. P J necrosis ,# " : & 3 & / 5 nitrate reduction 3 5 necrotic ulcer 0 G & 0 N> nitric oxide 2 J 113 English-Arabic nitric oxide synthase 2 J D+ 8 & nontranscribed spacer 0 5 2 & < 9 B & nitrification 0 nontraumatic ,# : < nitrifying bacteria 0 J nonvolatile 1 H < nitrilase ( ) normalizing selection ,#" H @ / ,#" H E 5 nitrite 3 northern blotting C f H ; nitrocellulose N N; 2 northern corn rootworm 01 &6- 9 W% % * 9 nitrogen cycle * 9 northern hybridization # & - * A nitrogen fixation * 3 C nos terminator K # A & nitrogen metabolism * ! nosocomial spread ,/ $ - 2 & - nitrogenase system #& Q * ! Y notification ^ ; nitrogenous base 0 * 9 B > novel trait 0 P & < 0 $ 8 no-observed adverse ,# I & ,# ;12 CQ T 2 & nozzle 9 R 8 i & 0 / % % effects level nuclear DNA ,/ no-observed effects level ,# I & CQ T 2 & nuclear envelope 9 W < &U @ 2 &3 َ َ وِ no-tillage crop 0 C 8 & 4 nuclear hormone receptor 8 &2 H R # َ َ وِ يّ production nuclear magnetic nod gene &6 B G " S & resonance a 2 َ َ وِ يّ node 9 @ B nuclear matrix protein &2 @ َ َ وِ يّ nodulation @ " * / W@ " nuclear receptor @ َ َ وِ يّ / َ َ وِ يّ nodule 9 @ B nuclear transfer non-coding parts of a 1& ] SG & & * nuclease (,/ ! & ) ;J gene nucleic acid ,/ ! & non-consumptive value 0 J ; A 2 & < 0 & > nucleic acid hybridization ,/ !& * A non-equilibrium theory 01 Y nucleic acid probe ,/ ! & ,K * & َِة َ َ وِ َّ non-exclusive goods 01 I C 2 < 0 B : nucleic base non-point source 1 & < 8 & nuclein ( 5 T N 91 &) I ; J N non-starch ,/ - ] 3 1 6J 2 B nucleocapsid 9 1 & 0 8 $ N> polysaccharide nucleoid ,# non-use value 0 " < 0 & > nucleolus 01 N nonenteric ,/ " & < / ,/ " & ] nucleophilic group 9 6 V 0 B & * & nonessential amino acid ,# 2 2 < # & ! & nucleoplasm 9 6 0 ; * nonheme-iron protein 1 D & H ] nucleoprotein ,/ noninvasive - & < / /G " & < nucleoside ; J N nonmass casualty agent 1 & > & B nucleoside analog ; J N C & & nonpolar group 01 HN> ] 0 B & * & nucleoside diphosphate ; J N 3 $2 $ # I NC 6J 2 nonproliferation - & < sugar nonsense codon 0 & B 9 & / 01 I U 9 & nucleosome ,/ 2 * 0 & @ nucleotid ; J N nonsense mutation 0 & @ 0 & B 9 $ H / 01 I U 9 $ H nucleotide ; J N nonspecific symptom 1 & < ! B nucleus 9 nontarget organism A 2 & < ,# I J null hypothesis H 01 : 114 English-Arabic null model H 4 % & opsonin , : 2 & H 91 & ) 0 U H nutraceuticals 01 $ Y 01 I % < 3 : 2 & (0 & " ; ; ? A& nutriceuticals 01 G 8 01 I % < 3 : 2 & opsonization 0 A H nutricine 2 optical activity ,/ 8 H - nutrigenomics ,# C 0 % R ; B optimum food C & " H nutritional epigenetics ,# I % < =W; 56 ; B optimum pH 7 ; C & 01 B > 01 : & optimum temperature 7 ; C & 9 O option value 5 0 & > optrode ,/ 8 ,K * & obligate aerobic ,/ * ,# I U organ : B observational study 0 > & 0 2 organ culture : BQ occurrence S organelle 01 : B ochratoxin 2 J N J c organism ,# I J / ,# odorant binding protein 0 I % H organisms with novel 9 3 $ 8 3 % 01 3 I J oil-free 3 1 & # 5 traits oleate (,# ) 3 I c organogenesis : BVQ =W; 5 oleic acid I cQ !& origin P - & oleosome 01 3 & 2 * origin of replication J P - & oligionucleotide ; J N ; > oropharyngeal ,# & " ; ,/ & oligofructan J ; > orphan drug oligofructose 0 A J $ J 2 ; > orphan gene SG & oligomer 3 & ;> orphan receptor @ 2 & oligonucleotide ; J N ; > ortholog 0 A - & 3 CG &) 4 C oligonucleotide probe ; J N ;> ,K * & ( . = H B 3 * oligopeptide ; > orthophosphate cleavage 3 $2 C ] H - oligos R osmosis F : oligosaccharide 3 1 6J 2 ;> osmotic pressure ,# : H R : omega-3 fatty acid < 01 U. ! & Q & osmotin # ) & 0 " - & (3 1 * % oncogene ,# & S G & osteoarthritis ,# & Y B 8 N oncogenesis . J outbreak ( & ! &) i $ oncology Q ; B outcrossing ,# H ; 5 * A onset overatropinization ] 9 I 0 * " & oocyte 01 : 01 ; 5 overlapping gene = & 5 & SG & open environment 0 $ & 0VI overlapping reading E J & 9 > H open pollination \ $ & F @ ; frame open reading frame 0 $ & 9 > H oversight 8 @ & < P H 5 operator +R - & overt ,# ; B / F : operon (,# R 8 7;B 0 @ H & ) R - & overt release ,# ; B = H opportunistic infection 01 A T B overwinding opportunity cost (0"I : ) 0 ; 0 8 N$ 0$; J oxalate 3] 2 J c 115 English-Arabic oxalate oxidase 3] 2 J Q 2J (3 2 $ oxalic acid 2J Q !& parapatric speciation * ,/ H WJ - ) oxidant 2 JV` & 9 * & =H & . & 0* oxidase ( ) 2 Jc (0 $ ; 5 & 0VI S oxidation 9 2 J paraquat (, 2 ,# - B &) 3 J oxidation-reduction 9 2 J 5 B $ parasite $NH reaction Parasitic ,# ; $ NH oxidative 01 2 JV 0 $ 2 parasitic disease ,# ; $NH ! & phosphorylation parasitism W$ H oxidative stress 9 2 JQ A * parasitoid ,# ; $WH [ - oxidizing agent 9 2 JQ & B parataxonomist 8 ,# 8 8 5 Y oxygen consumption * 2 JQ A 2 paravertebral 3 1 6@ $; * & oxygen deficiency * 2 JcQ B parents oxygen deficient * 2 JQ Z > , * paresis (,#I * $ 5 ; - ) 5 atmosphere particle 2 * oxygen free radical *2J ) , # * 2 J % * particle cannon 2 * D & ( G H & particle gun 2 * 01 > oxygen supplementation * 2 JQ 0 : partition coefficient 2 @6 & " & oxygenase *2 Jc partitioning agent 2 @6 & Bc parturition (! 5 &) 9 ] P party concerned H Q ,# " & party of export 8 H pachymeningitis 0 * E A party of import 2 & H paclitaxel O : & ) 2J ;J party of origin 8Q H / P - & H (01 H 2 party of transit B H paint U passive immunity 0 ; B ] 0 B & paleontology 0 2 ; B) 0 C M ; B passive use value 0 ; B ] & " 2 0 & > (3 C 2 & pat gene 3 SG & palindrome Y & = 2 patent 5 9 palindromic sequence (0 ; @ - &) 9 Y & 0 ; 2 ; 2 pathogen ! & & palladium & / ; 8 B) pathogen toxin ! & & $ % (0 0B &*& pathogenesis ! & -N / ! & palliative +H ; & pathogenesis related ! &M palmitate 3 & protein palmitic acid & ! & pathogenic ,# : & E G 2 & / ! & & palytoxin ,# * & $ % pathogenic agent ! & & & B pandemic ,# I / F I * pathogenic organism ! & & I J papovavirus 01 0 2 pathognomonic ,#: & 8 paralytic cobra toxin ( ; -) ,# ; ; - J $ % pathologic ,# : & paralytic shellfish toxin ,# ; ; - & $ % pathologic process ! &M 01 ; & B paramyxoviridae & 0 ; 8 ) 01 H 5 & 3 2 pathophysiology ,# : & I Y ; B 116 English-Arabic pathway ; 2 & / 2 pharmacoenvirogenetics B $ ) ,# I 1 ,#I 0 C ; B pathway feedback 0 " * 0 %R6 2 0 J J & J6 D& 01 I & " mechanism [ * 2 & I J ,#C pattern biomarker 01 * % & 01 0 & 8 ( 1 ; patulin (, 2 ,/ : & ) pharmacogenetics ,# I 1 0 C ; B pedigree E 26 9 * - pharmacogenomics ,# I 1 * & ; B pentose (,# 2 & N5 J 2 ) pharmacognosy > @ " ; B pepsin 2 pharmacokinetics 01 I 1 I peptidase ( ) pharmacology 0 VQ ; B peptide pharmacophore 01 I 1 0,8 5 & peptide bond 01 0 H pharmacovigilance ,# I Y W@ peptide elongation factor 0 H & B pharming 3 CG & 0 B peptide mapping H H 5 / 0 " : & phenolic hormone # & U peptide nanotube = > ,/ E phenomics 0 2 ) ,# C A Y & ; B peptide T T J6 0 " & D& A Y & peptido-mimetic & (,# C peptidoglycan J ;< phenotype 01 ; J - NH / ,/ U Y H & peptidyl transferase ( ) $2 phenylalanine (,# & !& ) ] peptone N pheromone 01 2 * 0 B @ N / & per capita intake rate $ j " & phlebovirus (71& EG 2N ) 01 3 2 perforin ( ) phocomelia HVQ W@ $ periodicity 01 phosgene ;J #I C <) *2 periodontium G2 & 0 * 2 ( J peritoneal = $ 8 - < / * phosphatase ( ) $ 2N cavity/membrane phosphate group 3 $2 $ 0 B & * & peromyscus species I phosphate transporter 3 $2 $ 0 ; > 0CG & peroxidase ( ) 2J gene persistence 0 & 2 phosphate-group energy 3 $2 $ 0 B & * & 0 > H person Z 5 - phosphatidyl choline ( 2 ) $ 2N J personal ,# 8 5 - phosphatidyl serine $ 2N 2 pest free area (, A ) 3 p & 0 5 0 @ H & phosphinothricin (E - B &) 2 C $2 pest risk analysis (, A ) 3 p H 5 ; phosphinothricin 2 C $2 2Q > pesticide (, A ) 3 p & acetyltransferase ( ) pH 0 : & 0* K @ & 8 5 & phosphinotricine (E - B &) 2 $2 phage A ; & / 0 C B phosphodiester bond 2M 01 I NC 01 $ 2N 0H phage display 0 C " ! B phosphodiesterase ( ) 2 N$ 2N phagocyte 01 & " ; 01 ; 5 phospholipase ( ) N$ 2N phagocytic cell l " ; & / 01 & " ; 01 ; 5 phospholipid ,/ $ 2 ,# U phagocytize " ; phosphorus $ 2N$ 8 B phagocytosis 0 & " ; phosphorylation 7 3 $2 9 & 5 / 0 $ 2 phagosome (01 ; 5 # ) N; e * 117 English-Arabic phosphorylation potential 0 $ 2 $ A * pia mater (,# < & <) Q photon (,# I : , J 9 ) N N pica / ,#" H < "6H; / H > photoperiod 9 / 1:; !. "6 9 R 8 K > 9 (-12) 01 I : picogram ( <10 ) < J photophore # b : & : B) picorna (3 2 ' - ) J (0 & 2Q picornaviridae 0 ; 8 ) 01 NJ 3 2 $ photophosphorylation 01 I : 0 $ 2 (3 2 $ & photorhabdus luminescen (9 - ) 2 & K U piezoelectric ,# H R : A J photosynthesis ,# I : / ,# I : = ; 5 pink bollworm 6; 01 U S " 0 > photosynthetic ,# I : = ;5 9 $ 2 Pitt-3 3 – 3 phosphorylation placebo [ " ] / $N< phyletic evolution 0 "W- = +; " & ) ,/ "N- . H plague B H (01 01 plague meningitis # B 6H 12 E A phylogenetic 3] .2 . H plant 3 phylogenetic constraint 3] .2 . H @ plant functional attributes 01 $ Y 3 Z I 8 5 phylogenetic profiling 3] .2 . H B D H@ & plant hormone ,# & U phylum : # 2 I 2 >) 0 "N- / 0 ; > plant sterol ,# 2 (0 B 2> 91 B plant toxin ,# $ % physical map 01 I 0 H 5 plantibodies tm 0 ;* 2 & 0 & B 01 91 : & 2* physiologically active ? 1 * 2 B E6J & plantigen 8 & ,# : & + & compound plaque 0 N physiology : BQ I Y ; B plasma 1 8 & / & phytase ( ) plasma cell 8 & 5 / 01 & 01 ; 5 phytate 3 plasma membrane ,# U - < / ,# & - < phytic acid !& plasma protein & phyto-manufacturing 01 0 B 8 plasma protein binding & D& H phyto-sterol ,# 2 plasmalemma (,# & ) ,/ ; 5 - < phytoalexin 01 9 plasmid E J 0 * 0 ) 9 & phytochemical ,# ,# I & J (3 1 R 8 4 5 phytochrome (# # g 8) J plasminogen & + & phytoene E J & 9 R8 9 ) plasmocyte (0 & 01 ; 5) 0 & (0 plastid (9 2 ) 01 0 " 8 01 ; 5 phytoestrogen ,# * 2 plastidome 01 ;5 # 3 2 &*& phytohormone ,# & U platelet 0 $ 8 phytonutrient ,# /+% R & platelet activating factor F I $18 H - & B phytopharmaceutical 01 01 I 3 : 2 & platelet aggregation 3 $.8 K. J phytophthora ( $ " H ) C platelet-derived growth FI $18 =+; " & , &N & B phytoplankton 01 = B factor phytoremediation 3 5 2 S. ; 0 * " & platelet-derived wound B FI $18 =+; " & , &N & B phytosterols ,# 2 growth factor \ * phytotoxin ,# $ % platelet-derived wound B FI $18 =+; " & , &N & B 118 English-Arabic
healing factor \ * I polymorphonuclear T 6 9 G " & : 01 NJ plectonemic coiling e * 8 $&) 8 $& $ leukocyte (#* H J- ; polynucleotide ;J B pleiotrophy ,/ U 6Y H &6 . " polypeptide B pleiotropic ,/ U 6Y H & 6 G " & polyphenol $ B pleistocene 01 * * 3 . R 9 polyploid 01 R G8 ^ G8 G " & pleocytosis ,# B 5W I 12 5 9 C J polyribosome 3 & 2 1 B ployvalent `N J G " & polysaccharide 6J12 B pluripotent stem cell 3 N@ 9 G " & 01 B % * 5 polysome 3 & 2 1 B point mutation 01 H @N 9 $ H polyunsaturated fatty 0 " - & < 9 G " & 01 U ! & point-source K I 8 & acids poisoning .& 2 polyvalent vaccine `N J6 G " & \ @ polar group 01 HN> 0 B & * & population 6J 2 polar molecule ,# H N> e * population viability 6J 2 01 ; polar mutation 01 HN> 9 $ H analysis polarimeter E H @ 2] K @ & porin ( > #I -< ) polarity ENH @ porphyrins poly(A) polymerase ( ) A G " & & port FH2 & * ) polyacrylamide gel [ ; JQ G " & U (0"-Q [ [1* N / % polyacrylamide gel G " & ,# & U ,# A J port-a-cath (,/ A * ) 9 H 2 @ electrophoresis [ ; JQ portable spray & & % % polyadenylation 3 Q " % portal ,# polycation conjugate 3 J G " & @ & position effect D : & C polycistronic @ & G " & positional cloning ,# " : & L 2 2 polyclonal antibody I 26 G " & , : positive control ,# * WJ polyclonal response I 26 G " & 0 * 2 positive supercoiling ,# * # B $ polygalacturonase ( ) J * G " & post-transcriptional gene f 26 " 0 C G & 3 & 8 polygenic ,# I * / 3 CG & G " & silencing polyhydroxyalkanoate 3 J Q #2J U G " & post-transcriptional f 26 " & 0 * " & polyhydroxyalkanoic acid #2J U G " & !& processing 3 J Q post-translational 0 & * 6 " " polyhydroxylbutylate 3 #2J U G " & modification of protein polylinker ( # ) H M G " & postexposure ! j " ; X polymer ,# I & J E6J & / NC J & / & ; potassium ( G ,/ ; 8 B) 2 &; 6 6J - potassium iodide 2 polymerase ( ) & potential receiving 0VI @ 2 01 J& polymerase chain ,# ; 2 ; 2 & B $ environment reaction potentiates /G @ polymorphism J -VQ . " powder = 2 & polymorphonuclear 01 NJ / T 6 9 R & 0 1 & powdered = 2 granulocyte 0 818 $ & powered 0> 6H 1 & 119 English-Arabic poxvirus ,/ * 02 prodrome 9 prebiotics Q > product 0 ; 8 / a / a & precautionary approach % % 5 E ; 2 production environment 0 * & 0VI precautionary principle % % 5 & production function 0 * & 0 $ Y precautionary zone % % 5 0 @ H & production trait 0 * & 0 $ 8 preclinical ,/ 12 > proenzyme M 0 " ; H precursor / ; 2 / D 86 ; 01 1 91 & progeria L N- 0 " ; H progesterone ( & U) 2* predator K $ & programmed cell death a & & 01 ; 5 3 & prenatal diagnosis = 2) 9 ] > & Z 5 - prokaryote 9 6 ,# I (9 ] ; proline pressure H R : promoter 91 & E @ 2 G " N 9 1 & ) " & prevalence - (T 5 prevalence rate - M 1 " & pronucleus 9 6 0 " ; H prevalence survey - k F 2 & prophase (,/ ; 5 2 @ M # ) 1 V 6H prevention 0 > propionic acid !& previously-vaccinated 1" H & / ? @ 2 F6@ ; & , proprietary 01 J ; & 1* 2 & individual propylene glycol E % & E+H &) J ;< ; primary cell 01 1 V 01 ; 5 (3 1 ] 18 # primary forest 01 1 V 0 < prospective study 0 1 > 2 0 2 primary productivity 01 1 V 01 * prostaglandin 01 U ! & ) < 2 primary structure 01 1 V 0 (01 2 2 primary value 01 1 V 0 & > prostaglandin 2J 0 @+; 5 & primer &" 0 @H & / e / - & endoperoxide synthase ( ) < 2 0 C ; B # prostate (91 N<) 0 2 primosome # E6J &) #I 2* Prostatitis 0 2 E A 3 - E J ,/ : prosthetic group (3 # ) 0 & & : 0 B & * & (f.2 6 C protease (# ) prion E 2 0 3 I *) proteasome 01 3 6J &) 2 (T " (01 ; 5 3 +H N 01 ; 5 prior informed consent 0 @ 2 & 0 @ & % 5 proteasome inhibitor 2 HG C & private opportunity cost 0 8 56- 0 8 N$ 0 $N; J protectant 8 private value 018 5 0 & > protected area 0 18 & 0 @ H & proanthocyanidin ( 2 JP , : & ) 2 C protection of human 0VI 2 M 01 8 Y $ probe 5 2N 01 91 &) 2 & health and environment * " 7;B . "6 ; protective action zone ,# I > H - 0 @ H & (3 protective clothing 0 > E C probiotics 3 1 0 " ; H protein procaryote 9 6 ,# I protein array 0 & Y & process validation / 01 > 8 & = C & =W@ protein biochip ; 01 0 > > 01 > 8 & 01 B - protein bioreceptor ; ,/ @ 2 & 120 English-Arabic protein c c proto-oncogene ,# & SG & 0 " ; H protein chip 0 > > protocol a A & / 2 & / 01 1 V 3 U - & protein conformation 0VI U / J protoplasm 0 ; * protein engineering 0 2 U protoplast 9 1 * & 0 ; * protein exotoxin # # * 5 $ % protoplast fusion 9 1 * & 0 ; * 4 & protein expression " protoxin $ % 0VI protein folding (01 $ Y [ ) $ protozoa & 0 " N- ) ,# VQ 3 protein inclusion body ( & - & ) &1: 2* 3 1 1 / (01 0 J ; & & protein interaction B $ ; provirus K $ 0 " ; H analysis provitamin & $ 0 " ; H protein kinase ( ) J pruritic ,# +J protein kinase C C J pseudogene E % J SG & protein microarray ; 0 @ > 0 & Y & psi :HR : K > 9 ) / 2 protein quality 9 * (D1 & i J protein S S psoralen ,# Z ; 5 2 & ) 2 protein sequencer G A*) 0 ; 2 ; 2 & = A 4 B # 5 2 # 0 &Q ! & Q EN> " (01 8 ( 0 ; 2 ; 2 psoralene ,# Z ; 5 2 & ) 2 protein signaling -P = A 4 B # 5 2 protein splicing 8 / $ : (01 8 psychrophile 9 ; ,E & / ,/ i " & protein structure 0 psychrophilic enzyme ,/ i " & protein toxin $ % pterostilbene 9 2 JO , : &) 2 protein tyrosine kinase J (0AJ $ !" # * & protein tyrosine kinase J H C& public good 01 & & B 0 " ; 2 inhibitor puffer ( & 2VQ & K *) L N$ protein-based lithography 7;B ? & B " & 7;B 0 B H pungi stick #* 8 B pure culture 0 8 5 0 B & protein-coupled receptor 4 & @ 2 & purine protein-protein 5 D& B $ pus 8 / F > interaction push package 0 ; & J & 0 & proteinaceous infectious 01 I B 0 3 & 2 * pyralis (K .2 & K *) K particle pyranose (,# 2 2 6J 2 ) N proteolytic ; j pyrexia 0 5 2 / 71& proteolytic enzyme j pyrimidine & proteome ,# I J 3 0B &*& pyrogen 71& ; + & proteome chip I J 3 0 B & * & 0 > > pyrogenic toxin 71& ; + & $ % ,# pyrophosphate cleavage # I NC) 3 $2 H - proteomics G "N # 3 K ; B (3 $2 $ 3 I J # 01 C 91 & A B pyrrolizidine alkaloid [ - 01& 2 91 &) / ;> 01 (3 !" U $N 01 ; >
121 English-Arabic pyuria 01 > 0 ; random amplified ; # I - " +5 : & ) RAPD polymorphic DNA ( J-Q G " & Q randomized ? 1 I - B 5 & rapid microbial detection D 2 ,# J & - _ J quadrupole ion trap E H>Q 01 B 3 9 8 & ras gene A 3C % 0CG &) K 0CG & quantum dot ,# H @ N , J ( H 2 EG 2N 9 $ H quantum tag 01 & J 0 & B ras protein K 0 C G & a ) K quantum wire ,# & J ; 2 0 ;5 B : # 0> B [ quarantine pest 0 r ,# 8 * (a & & ,/ ;5 3 & quarantine ,# 8 * rash F $ H quasi-option value 0 & > / ,/ U Y 5 0 & > rational drug design ,# @ H & @ B & 8 ,# I * 5 rational expectation ,# @ H & D W> quaternary period 01 B 9 reactive oxygen species 01 ; B $ 01 " * *2J quaternary structure 01 B 0 0 R; 0 H - 0 *2J N% *) quelling D & > / eG A & 91 2J *2J 3 quencher dye 9 & 5 0 R 8 / 0VI $ H & 0 R 8 ( 01 ; 5 & 7;B & " quercetin "$& % EJ &) 2 J reading frame 9 @ H (#I B reagent 0 $ - J 91 & quick-stop D 2 W> reassociation H 6 9 B quinolone (/ , : & ) J recalcitrant seed 9 G & & % quorum sensing 01 2 3 I *) ,#2 E 8 receiving part @ 2 & H A . 8 =G2 N J ; receptor @ 2 & (3 -M receptor fitting @ 2 & receptor mapping @ 2 & H H 5 R receptor population @ 2 & / 3 @ 2 & &* & ,# 6J 2 racemate ? I : 1" < a &) 3 & 2 receptor tyrosine kinase J + @ 2 & ( G2 & G& & < 8 & ( ) racemic ,# & 2 receptor-mediated 3 @ 2 & 9 B 2 & @ radiation " - endocytosis radicular ,/ % * recessive (# &) hF & radioactive ? 1 B "- H - / ,D - & recessive allele (# &) hF & radioactive isotope ,D - & Y recessive gene hF & S G & radioimmunoassay 01 B "N- 01 B & 0 2 @ & recessive oncogene hF & ,# & S G & ُ َ - دَ ل 7 رِ radioimmunotechnique 01 B "W- 01 B & 01 @ reciprocal externality ً . ِ6 radioisotope ,D - & Y recognition sequence 0 1 " & 0 ; 2 ; 2 radiolabeled 01" - & 91 & 6; " & (site) radiotherapy 01" -Q 4 B / 01 B " - 0 * " & recombinant M 9 B 4 ) E -P & raft H (#C raman optical activity & 01 @ ? 1 8 6H Y recombinant DNA G & / E -P & spectroscopy recombinase (EW-P ) & J 122 English-Arabic recombination (EW-P ) + M 9 B replication f.2 / . J recombination frequency 3 -P & B) EW-P . replication fork B :6 0 J - ( 2 ; #;NJ " 7;B ? & 2@& replicon & #$ Y *) NJ ; red blood cell & 1 01 J ( redement napole # 0 CG &) 3 & reporter gene 5 & SG & 0: & CJ a 5 repressible enzyme Y J; > (#" H ; & repression Y J redness S # 0@H & ? C &) & repressor SG & A * 91 &) 0 & Y J (E A A ( Y J reduction Z @ residual risk 3 +@ & H 5 redundancy & / 0* B 9 / 9 residue (#+@ &) u= & reference concentration ,# " * & J resource & reference laboratory ,# " * & 5 & respirable KW$ 6 ; F 8 refillable 0 C &k > respiration KW$ refractile body 2 J M A 2 2 * respiratory distress 01 2W$ 0 @ I : refraction 2 J respiratory mucosa ,# 2 W$ ,# H 5 & - < regeneration 0 * 2 Q . * respiratory tract (,# 2 W$ A *) ,# 2 W$ 2 regulatory element +Y & 8 B response 0 * 2 regulatory enzyme +Y & restoration 2 regulatory gene +Y & SG & restriction endonuclease H >] ,# ; 5 ;J regulatory sequence " +Y = 2) +Y & = 2 restriction enzyme H > 3 & (SG & restriction fragment 3 N- J - . " rehydration A & / I 12 ! " length polymorphism relapse ? 1 * / K J restriction map H >M 0H 5 relaxed circle plasmid # 5 2 & #@ ; & restriction site D H @ D > & relaxed plasmid # 5 2 & & restrictive enzyme D+H @ & remediation 0 * " & resuscitation i " renaturation 0 " 6H 9 " 2 / J 9 B resveratrol &" ,# E6J &) renature 0 " 6H " d $H6 ; , : & d 2 JP ; , : &J renin HR: Y ,/ ;J ) (E A k , : & ( 1 retinoid / ,# [ - / J6- ,# renin inhibitor HG C & 01 J 6- [ - rennin WC 5 ) 0 $ M 9 &5 retinoid X receptor J6- ,# X @ 2 & (E ; retroelement = 2 8 B reoviridae A * E 8N ) 01 3 2 retrograde ,# 2J B a / ,# " * a (,# 2 N$ 6 retropharyngeal " ; & reovirus ,# 2W$ K ) ,/ K retrospective diagnosis = 2 Z 5 - (,/ " & retroviral vecto 0; > 01 B * 3 2 reperfusion D HN> :BQ) 1 =W 9 " 2 retrovirus ,# B * K " 08 5 1 & A B revealed preference A Y & : $ E ; 2 (0 ;> 0 % 0 8M approach 123 English-Arabic reverse genetics K J " & 0C ; B RNA ,/ 6 !& 8 5 &) reverse osmosis ,# 2 J B F : (# G reverse phase ,# 2 J B E - 2 H RNA interference 1 N5 chromatography RNA polymerase ( ) 1 & reverse transcriptase & ) 01 2 J B 0 5 2 & RNA probe 1 ,K * & / 1 2 & ( [1* & RNA processing 1 D 8 / 1 0 * " & reversed micelle 2 * :0 ; % &) 0 2 J " & 0 ; % & RNA transcriptase 1 0 5 2 & (0 < [ - 9 & # E A J & RNA vector 1 & Rh & / #2 1 & " 8 5 & rocket * * 3 / L 8 8 B rootworm % * 9 rhabdoviridae 01 3 2 rosemarinic acid 8 !& rhizobia # * 0 G C & J roving gene 1 * SG & 0 N rRNA ,#& 2 rhizobium 9 % * / * 0 G C & J rubitecan % ,# H @ B 2 ) J rhizoremediation 0 G C & J H.2 9 B ! & , : 01 * B 01 " * ( H 12 rhizosphere 9 % * H & < rubratoxin ,/ H $ % rho factor 3 1 I # f 26 A rumen (3 1 * & # ) i NJ 9 6 rumenic acid & !& rhodanese NJ & & $ rust (E 8) 8 ribonucleic acid ,/ ,/ ! & ribose (,# 2 & N5 6J 2 ) S ribosomal adaptor ,#& 2 @ 2 & ribosomal ribonucleic ,# & 2 ,/ ! & safe minimum standard 7 Q &Q 1 " & acid safe safety 0 &P & 0 & 2 ribosomal RNA ,#& 2 safe transfer & @ ribosome 2 safety factor 0 & 12 & " & ribosome-binding site 2 H D > & safety-pin morphology ,# ; J 6- E J 6 & 1& 8 riboswitch 01 & 2 0 1 salicylic acid ; 2 12 !& ribozyme salinity tolerance 0 N; & .& rice blast (,/ H ! &) , Q 0 $ salmonella & C * K *) 0 ; & ; 2 ricin % # 01& 2 91 & ) 2 (3 1 I " &VQ ( 5 salmonella enteritidis " &VO 0 A ; & 0 ; & ; 2 risk H 5 & salmonella typhimurium l 01 _P 01 $ 0 ; & ; 2 risk assessment 9 H 5 & @ salt tolerance F ; & .& risk factor 9 H 5 & & B salting out F ; & E 2 risk management 9 H 5 & 9 saponification . 8 risk patient H 5 ! & saponin & 0B &*&) 8 risk ratio 9 H 5 & 1 " & (3 J ;R risk reduction 9 H 5 & ;@ saponnin 8 risk worker H 5 & B SARS 91 01 VI T " 0 & & 124 English-Arabic satellite DNA D / 2 sequence homology # & = H satellite RNA D / 2 sequence hypothesis D 6 01 Y satratoxin ,/ H $ % sequence map D 6 0 H 5 saturated fatty acid D - & ,# U !& sequence-tagged site 2 ; 2 3 & B D > & saxitoxin # ,# 8B $ %) 2 J N 2 J 2 sequencing # / E / 2 ; 2 (3 5 sequon ( N ) J 2 scab E * / 0 ; * serial analysis of gene ,#C "6 ; 2 ; 2 & ; scale-up G H expression scanning tunneling E J2 J & ,# 2 & A* 2 serine (# & !& ) 2 electron microscopy ,# @ $ 6 seroconversion E @ ) 8 & 0, ; B $ E @ secondary forest 01 C 0 < (,#* 2 secondary pneumonic B H / ,/ C ,/ VI B H serologist 8 &Q ,#8 8 5 plague 1 serology * 2 / 8&Q ; B secondary value 01 C 0 & > seronegative 8 & ,# ; 2 seed bank % serotonin 0 1" 0 8B 91 & ) N 2 seed-specific promoter 9 % ; ,# B +$ & (0 B Q # seedless fruit 01 % ] 0 A J serotype ,# ; 8 & H & seizure 8 0 serum 8 & selectable marker ,/ 5 2 serum albumin 8 & & V selectable marker gene ,/ 5 2 SG & serum half life 8 & & B 8 selection @ serum immune response 8 &; 01 B & 0 * 2 selective estrogen effect * 2k #I @ CP serum lifetime 8 & & B selective estrogen #I @ M @ 2 & FG: & sessile ,# @ N B ] / b H] receptor modulator * 2k settle EG2 / +H self-assembling # I * # % D & * 0 settling E 2 molecular machine sex chromosome ,# 2 * ,# R 8 self-assembly D & *6 ,# % sexual conjugation ,# 2 * > self-pollination F @;6 ,# % sexual reproduction ,# 2 * NC J / ,# 2 * N semiconservative ? 1 I * Y & B : sexually transmitted ? 1 2 * @ ! & replication disease semisynthetic catalytic 91 : & 2*O ,# I * = ; 5 Shelter-in-place P *; & antibody 01 $ 6 shiga toxin 01 . 06; R - $ % senescence 0 5 5 - shock 0 & 8 sense 0,2 / ' *+ short interfering RNA 5 & 8> sensitivity K.2 / 01 2 2 shotgun cloning method ,# > L 2 2 M 0 @ H sentinel surveillance ,/ $ 5 & .8 shotgun sequencing ,#> 2 ; 2 sepsis showering septic shock 01 0 & 8 shuttle vector ,# J WJ & > & sequela ! & 0* ) ,/ C / @ B sialic acid 12 !& ( & sibling species = @ - sequence 0 ; 2; 2 & / 0 & side effect ,# * C P 125 English-Arabic signal transduction 9 -M ^ smoke 5 signaling +-V` smut (# #; $H ! &) 1 2 signaling molecule +-V` & e * social opportunity cost 01 B & *M 0 8 N$ 0$;NJ signaling protein +- V` & sodium 8 8 B silencing 3 & 8 sodium dodecyl sulfate 3 $;2 2 8 silent mutation 0 & 8 9 $ H C12H25SO4Na silica ( 2; 2 2J ,#I C) J ; 2 sodium lauryl sulfate 3 $;2 8 silk C12H25SO4SNa silviculture 3 R ; B sodium phosphate 8 3 $2 simple protein H 2 sodium sulfite 8 3 $; 2 simple sequence repeat H 2 E > " & J soft laser desorption $5 Y $ simulation 9 J & / ! & solanaceae 3 1 * % sin nombre virus 01 2 0&;J) & 2 K solanine (# 8@ ) ] 2 0;I " & 2 K # " solid E ; 8 / & * (01 solid support E ; 8 B sindbis virus 02 $ ) K 2 K solid-phase synthesis E ; 8 H (71& EG 2N # 01 $ Q soluble (j ; >) E 1 % single-cell protein 01 ; 5 / soluble fiber 0 1 % single-nucleotide ; J N / J- . " somaclonal variation 01 & 2 * 5 5 polymorphism somalia & .8 single-stranded DNA 0 ; 2 ; 2 0 * / soman & ,#I & J \ 2) & 2 single-walled carbon J 01 0@ > E , 2 RJ &" $2$ 3 6J & nanotube / * (0 8" 3 A 7;B sirtuin ( ) 2 somatacrin (, &N ; & U) J & 2 site-directed mutagenesis [1* & D > & $H somatic ,# & 2 * / ,/ 2 * sitostanol &" 0 & J 91 &) 2 2 somatic cell 01 & 2 * 01 ; 5 2 J 0 2 ! $5 7;B somatic cell gene therapy 01 & 2 * 01 ; 5 01 C 0 * " & ( 1 # somatic variant ? 1 & 2 * ; 5 & sitosterol * 3] 2) 2 2 somatomedin U $ 3 6J &) & & 2 0 B J 3 !" # ( Y " J [ J 3 & A = ;5 7;B B 2 somatostatin ' $N & U) 2 & 2 (0 2 # / 8 2 3 5 sizing 01 < 91 & (g &G skin ; * somatotrophin (, & N & U ) 01 2 * 0 G& & slime (0 < 0 * 91 &) H somatotropin (, & N & U ) 01 2 * 0 AG* & slough \ * 9 - > sonic hedgehog protein 2 / ,# 8 ,/ % N$ N> small interfering RNA R 8 5 & A* U small nuclear RNA R 8 ,/ SOS protein B `2& ) K 2 small RNA R18 9 B 2& & " = H $ small ubiquitin-related R 8 ,# J G " & ( \ 8 0 ;&B # modifier SOS repair system & ) K 2 \ 8 Y 126 English-Arabic
& 0$ 0 * B @ spray % / L 65 ( sprayer i & SOS response 0 * 2M 0 ) K 2 0 * 2 spreader 0 - ( # ;5 \ 8 0 ;&" squalamine &2 J & , : &) & J2 southern blot analysis ; ) %2 0 5 H ; 4 " 0 [ & Z;5 2N i @ & " & H& 5 2 ( H 2 (0 ;5 # squalene & Z;5 2 91 &) J2 southern blotting / 5 ; ) %2 f H ; (i @ &2 = H C & Z $ stability L 2 / 3 C / @ 2 ( 3 I * stabilizing selection ,# C @ southern hybridization %2 ; ) %2 * A stacchyose a 0 3 1 6J 2 ) J 2 ( # *A 0 ;&" ( 8 & ? " H southwestern blot 0@ H) 2 C 2 05H stachyose 3 # #B 6J 2) J 2 H & B -J; (# 8 #J - #: Q (#& A 1 5 2 stacked gene Y 0 21 J & 3 CG & speciation / H WJ - ) staggered cut & & D H > ( * standard ,# 2 > / ,/ " & species stanley bostitch oil-free #; 2 – ,# ] ,# I U H < : species diversity Q . " air compressor i 2 species richness Q 9 stanol ester 0 ;8 0 NJ 91 &) 2 2 species selection Q 5 (/ :B F;& D& species specific 1 & ,Z 5 stanol fatty acid ester 91 &) 2 ,# U !& 2 specific activity ,# B H - F;& # U !& D& 0 J specificity 01 B (/ :B spectrometer 6H K @ & staphylococcal 9 1 J & J =+; " &) ,/ @ B spectrophotometer ,# I 1: 6H K @ & (01 @ " spectrum H staphylococcal ,/ " & $ % ; 0 1 @ B 9 1 J & spermophilus (! @ & K *) > U enterotoxin spinning D 2 / < staphylococcal toxin 01 $ % 01 @ B 9 1 J & spinosad (/ - &) 2 2 staphylococcus & K * ) 9 1 J & spinosyn (/ - &) 2 2 ( J spirochete (0 & C *) 0 ; & staphylococcus aureus 9 1 J & splice variant 0 & 9 $ : starch - spliceosome # e *) 2 2 2 startpoint 0H@N / = H 0H@N 2 & 8 7;B B 2 stationary phase ! " # ) @ 2 ] H (9 0 @ @ 0 ;5 # ( splicing $ : stearate !& & 2 F;&) 3 2 splicing junction 9 $1: 8+ ( 2 spontaneous assembly ,# I @ ; D .& * stearic acid 2 !& spore g stearidonate & a 01 U 91 &) 3 2 sporulation g. (3 !" % 127 English-Arabic stearidonic acid !& ) 2 !& structural gene ,# J SG & % ? 1 " H [ * N #2 2 # U structural genomics ,# *& E J (E6 @ 3 structural proteomics ,# E J stearoyl-acp desaturase # U. !& - " structure E J / 0, stem cell 01 B % * 01 ; 5 structure-activity model ,# J H - 4 % & stem cell growth factor 01 B % * 5 , &N & B structure-functionalism E J 6 0 1 $ I Y stem cell bone & 01 B % * 5 P - & 01 ; 5 subclinical ,/ 12 Y " 5N subcloning L 2 2M stereoisomer ,# < g 8 & submunition 01 @ B > / ,# I * F ; 2 steric hindrance 01 & 2 * 0> B subspecies D N sterile @ B substantial equivalence ,/ & `N J sterile water 6@ " & & substantially equivalent ,#;" b J & sterilization @ " substitution 2 steroid (0 @ ; 3 ) 2 substrate B $6 9 B > / 9 J sterol % / 2 EJ &) 2 sugar molecule 6J 2 e * 7;B 0; H 0 $ 0 * 0;2;2 sulfate reducing 3 J 0 5 & J (17 > J bacterium sticky end (0 @ 8]) 0 > 8 0 A sulforaphane * H 12; , : &) $;2 stigmasterol (,# 2) 2 &R 2 (#;J 3 # stochastic 3 R &; ) ,# I - B 2 ; 2 sulfosate (# J E -B &) 3 2 $;2 (0 I -" superactivated 1" H - stomatal pore RWC 0U1 / ,# U , 2 & superantigen ,# > , : 2 & stop codon W> 6 9 & supercoiled plasmid $ M C J & storage protein ,# 5 supercoiling $ M C J strain 0 2 / 01 G N% supercritical carbon ? * 4 J 2J # C strand 0 ; * / 0 ; 2 ; 2 / = H dioxide streptavidin #B ) 2 supercritical fluid = 52 ) 3 C 4 I 2 [ - 3 I J [* 3 & 2N@ 0* 3 ;R 0* (3 H $ (0;I 2 0 # 7@ &* streptococcal (3 1 @ " J =+; " &) ,/ @ B supergene 0 @ I 3 CG & streptococcal enterotoxin ,/ " & $ % 3 1 @ B supernatant (# H) u H streptococcus ( J & K *) 01 @ B superoxide dismutase ) &2 2J 2 streptococcus mutan 9 H 01 @ B ( 2JQ = ; stress protein A*M superparamagnetic 0 H R & & = 01 3 VI * stringency 0 & 8 / >M - nanoparticle stringent plasmid - & / 8 & supportive care 0 & B 0 B stromelysin # N5 ) 2 & 2 suppressor gene 3 J SG & (0 ;5; 0 ;5 0 H suppressor mutation 0 J 9 $ H strong sustainable 3 C . H6 & suppressor t cell 0 J t 5 development principle suppuration F. @ structural biology ,# J Q ; B supramolecular assembly & 6 V` &) ,# I * = D .& * 128 English-Arabic
(3 I * 91 B surface plasmon 0 * 91 & ) ,# H 2 & systemic inflammatory 01 A * 0 * 2M 0& & (9 4 5 response syndrome E A k surface plasmon ,# H 2 & systeomics a& ) 0 &Y 3 1 @ resonance KJ& * dKJ& surfactant 9 - 91 & / F H12 B (KJ & surplus embryo ! I * surrogate market = 2 T sustainable 0 & 2 & sustainable development 2 & H t lymphocytes 01 $ &+; T 5 Sustainable 4 M 0 & Y Q 2 & CJ T-cell T 0 ;5 intensification of animal ,# T-cell dependent T 5 9 & " & 01 production systems mechanism sustainable use 2 & 5 2 T-cell growth factor T 5 , & N & B swingfog B / E+; @ & / F * P & i - T-cell independent T 5 06; @ 2 & 01 @ 2 mechanism switch protein G & / G & T-cell modulating peptide T 5 G " & syk protein 2 T-cell receptor T 5 @ 2 & symbiosis i " T-DNA T symbiotic i " & T-shell T < sympatric H & 9 6 & tabun (, 2 # 8B <) sympatric speciation H & 9 6 & 3 I J tachykinin & 0B &*&) J J 3 @ 2 & ( * / H WJ- ) (3 symptom ! B tachypnea K $6 . 2 symptomatic (! BP E 8 &) ,# : B tag 0 & B synapse - & tandem affinity 0 @ 6 0 $ 01 2 synapsis - purification tagging synaptic cleft ,# J - & f ; tannin + 6 !& synaptic gap 01 J - 9 * tap tagging 8 2 synaptotagmin (,/ , : & ) &* 2 taq DNA polymerase ( ) & syndrome ! B / 0 & & taq polymerase ( ) & synergistic effect E 8 & CP / ` & CP target U synovial ,# ; target validation A 01 B - synthase ( ) C 2 target-ligand interaction UQ N5 & - F 2 & synthesizing = ; 5 screening synthetase ( ) C 2 / 0 @+; 5 & tata homology K * & syrup of ipecac E U6% = B E - taxol 0 O 0 * 0 & B) 2J systematic activated ,/ A * 0 & @ & H - ( H 12 ! & 91 : & resistance taxon 0 N 8 systematics ,# * A & Y / ,/ A * Y taxonomy 86 ; B systemic acquired 01 A * 0 2 J & 0 B & technical testing ,# @ Z 129 English-Arabic technology * J threonine (,# & !& ) C technology protection * J 0 & Y threshold concentration 0 " J system thrombin ( 1 HW; * ) & C telomerase 2@ # B 2 ) & ; thrombolytic agent 9 C 5 j (,#R G8 0 A H B 0 ;5 thrombomodulin ) & & C telomere (3 1 R G8; ) ,# H 2 N> (#I - < temperature 9 0 * thrombosis CN5 template E > / 8 & thrombus 9 C 5 / 0 H ; * teosinte E * 8) 9 N% * U thymidine kinase 91 NR =;" & ) J & C (#J & (0 B1 teratogenesis 01 @ ; 5 3 U. - / L 2& thymine ( # 01 9 B >) & C teratogenic compound f 2 & E6J & thymoleptics , : & ,# I , @ B ) KJ & C termination codon A M 9 & (E I Jk terminator # A & thyroid stimulating 01 > 0 AG* & terminator cassette # A & 0 ; B hormone terminator region 0 A+ 0@ H & tissue a 2 terminator sequence 0 A+ 0 & tissue array 0 * 2 0 & Y & terpene 4 5 2 / HB EJ &) tissue culture 0 * 2 0 B (3 & tissue engineering 0 * 2 0 2 U terpenoid ,# [ - tissue plasminogen & + & 0 * 2 H+- & tertiary period (#* * 8 B) ,# C C 8 B activator ( ) tertiary structure " Q ,# C NC E J tissue-necrosis 0 * 2 3 & test-range Z $ T & titer B testosterone ( & U) 2 2 tocopherols 3 1 NJ 0 B & * &) J tetanus toxin NJ $ % (E & A & U. 0 1 % tetrahydrofolic acid & ,#B $ !& tocotrienol ,/ > 9 2 J , : & ) J tetraploid 01 R G8 0 R G8 ,# B ( J D& E & G J & thale cress 3 DI - 2M ) K J C togaviridae 01 I 5 H 3 2 (Arabidopsis thaliana tolerance .& theory of local existence ,# ; & * 0 Y toll-like receptor ,# I -< > @ 2 & thermal ,/ TOPAS aerosol E I : إِْء thermal hysteresis protein ,/ `NJ topotaxis thermoduric 9 ; & 8 total economic value 01 ;NJ 01 8 > 0 & > thermophile (,E & ) 9 total environmental value 01 ;NJ 01 I 0 & > thermophilic bacteria 9 0$ J total internal reflecton ? 1 ; 5 K J " & =W P & * & thioesterase ( ) 2 C fluorescence thiol group 91 % 3 J 91 % / 3 J & totipotency &N- / & 7;B 01 % 9 N> * U D 2 thioredoxin 5 3 ) 2J C totipotent stem cell &6 7;B 9 > 01 B % * 01 ; 5 ( C 3 J & 5 # toxemia 1 .& 2 threatened species 9 1 A & toxic molecule , 2 e * 130 English-Arabic toxicity 01 G& 2 transcutaneous ; * B toxicity characteristic & .2 ; G & & F - 6 * transdermal 0 & Q B leaching procedure transducing phage 0 R 0 C B toxicogenomics &.2 + & transduction 91 & = NH &) ^ toxin 01& 2 91 & / $ % ,K / ( C * # 01 C toxin agent ! Q B $ ,# G& 2 & B transfection !& 01 ;5 T B) " toxin weapon , 2 \ 2 [$ B : , C d & K $ ,/ toxoid ( 6H " & $ %) % (0 ;5 ; # toxoplasma / (3 1 1 Q & K *) 0 21 @ & Transfer J & / @ / @ (3 1 ; $WH & ) 3 1 < transfer DNA > tracer ( 2 9 ) 0 $ I > transfer factor > & B traditional breeding 01 ;@ 0 0 @ H transfer RNA > method Transferase ( @ M $ ) 0 ; > traditional breeding 01 ;@ 0 01 @ transferred DNA 1 & technique Transferring N@ ;< ) $2 trait (0 & 2) 06; 5 ( 1 & # trans fatty acid = $ & ,# U !& transferrin receptor $2 @ 2 & trans-acting protein > H - % transformant 5 s ? 1 C 1 N 01 ; 5) 0 1 & transactivating protein @6 G" $ (E < transactivation @ " $ transformation 0 2 / . / transaminase ( ) &Q 0 ; > transformation efficiency 6 9 $ J transamination &Q @ transforming oncogene G & ,#& SG & transboundary harm ,/ G : transgalacto-oligosacchar J *; 0 ; > 3 1 6J 2 0; ;> transboundary movement 01 G 0 J ides transboundary release ,/ G = H transgene B SG & transboundary transfer ,/ G @ transgenesis ,#C " transcapsidation K $ ,/ 6 !& ; R transgenic ? 1 C V 1 " & # H R & transgenic animal ? 1 C V 1 " & transcript 0 5 2N transgenic plant ? 1 C 1 " & 3 transcriptase ( ) 0 5 2 & transgressive segregation 5 & 8_ transcription f 2 transit peptide ,/ B transcription activator f 26 H+- & transition @ transcription factor f 26 & B transition state 01 @ 0 ; & transcription factor f 26 & B H D > & transition-state 0 HG2 & 01 @ 0 ; & binding site intermediate transcription unit f 26 9 translation 0 & * transcriptional activator ,# 5 2 H +- & translocation ( 5 7 D > & & @ ) transcriptional profiling ,# 5 2 DH@ & transmembrane protein 0 - transcriptional repressor ,# 5 2 F J transmembrane regulator 0 -
(01 ; 5 transposable element @ & * & 1 & 8 B tularemia # I B ! &) 01 & ] transposable genetic * & 1 & ,# C 8 B ( 8& # / J element @ & tularemia E Q 71& transposase 1 D H > > tumor transposition (0 ; > &) D : R tumor DNA transposon #& C * 1 & *) N@ tumor marker 2 ( 0& @& ? * @ tumor necrosis factor 3 & & B transversion ) tumor virus ,# & K ( 1 # & tumor-associated antigen =+; " & , : 2 & treatment system 0 * " & Y tumor-inducing plasmid S & trehalose ' $N #I NC 6J 2) N U H tumor-suppressor gene D & SG & (3 - !" tumor-suppressor protein D & tremorgenic indole ,/ ; > ,# i B G J & turbidity 9 NJ B alkaloid turnover number ,# W; @ B triacyglyceride 2;* 2 #C NC two-dimensional " Q ,# I NC triacylglycerol 2 ;R 2 #C NC two-hybrid system ,# I NC * A Y trichoderma harzianum & K * ) 0 & 3 1 " - type specimen ,# H & 4 % & (0 3 1 H typhoidal tularemia E Q 71& /01 $ 01 & ] trichosanthin ? 1 C 1 " & , 01 $ trichothecene mycotoxin [ * N ,/ H $ % ) 2C J tyrosine (,# & !& ) ( H I 8 tyrosine kinase inhibitor J HG C & tricothecene (,/ H $ % ) 2C J triglyceride 2 ;R #C NC U triploid 01 R G8 0 R G8 ,# C NC tRNA ,/ 6 # G !& 8 5 & ubiquinone # ,#& - E6J & ) J 6@ (3 G @ & - < trombone (0 @ 2 & 0 ) = ubiquitin B E6J &) J trophic ,# I % < [ 01 5 # * trophic level ,# I % < T 2 & ( ; # tropism [.* / ubiquitin-proteasome 2 J ; 2 & truck 0 - D I : 0 B pathway trypsin ( W; ) 2 ubiquitinated J =+; " & trypsin inhibitor 2 HG C & ulceration 0 @ . J / \. @ tryptophan (# & !& ) ulceroglandular tularemia 01 . @ 01 G N< 0 & ] tuberculin ,# I 2) J ultracentrifuge 0@ I 9 % & / = I ,/ J & H # 5 2 6@" & ,/ J ultrafiltration = I F - (j 2 3 5 ultrasonic ,# 8 = tuberculosis . / j 2 ula 0jtC 132 English-Arabic umbrella species 06; Y & validation 01 > 8 & = C & =W@ uncertainty factor , 6- & B valine (,#2 2 ,# & !& ) unconfined release * & < = H valuation @ / 9 1 @ & 0 & > uncontaminated water S1 ; & < & van 0 & / 0 @ ; R & @ 0 B unidirectional externality ? 1 * 5 ' * + M vancomycin (,/ , : & ) 2 & J unimmunized individual 18 & <) D6 & & < variable surface FH12 G R & ,/ 6J 2 (0 B & glycoprotein unintended release 8 @ & < = H variance 3 $ unintended transboundary 0 "> & < 01 G 0 J variation 5 movement vascular endothelium ,# I B 01 &1 0 B Q 0 H unit 9 vasodilator 0 B O DG2 & unsaturated fatty acid D - & < ,# U !& vector > unwinding protein X ; & < vector borne & & > upstream 1 , : vegetative cell 01 01 ; 5 uptake WC & / H > / Z 8 & vehicle 5 2N 01 * B < 91 &) g 2 uracil # 0 * 9 B >) 2 (? 1 ] 8 0 H 2 J ( vent % $ & / 4 5 & urease W; G " ) vernalization ! " U M * " ) ( (7 9 3 6 uridine B ! = 2&) vertical gene transfer ? & B SG & @ E * # 5 2 0 I vesicle 0 ; 8 (01 & J vesicular transport ,# ; 8 @ urokinase # ) J vesicule ,# ; 8 * ( 2 M vibrio cholerae 01 J 01& : use &" 2 vicariant pattern EI 4% & use value &" 2M 0 & > viral ,# 2 user D $ & / & " 2 & viral agent ,#2 & B utility function 0 " $ & 06 viral encephalitis ,# 2 $ g & G E A uv 01 * 2 $ = 8 5 & viral hemorrhagic fever 01 2 01 71& viral transactivating B : +$ & V protein 3 2 $ virion ,# I B ,# 2 e * ) v antigen v , : 2 & (# - R H & vaccine \ @ viroid J6- ,#2 vaccinia ( @ ,/ * ) K_t> virulence (K $ 91 -) 0 B vacuole * / 9 * virulent ( 1 $ &) - vagile 0 * 2M 7;B > ,# I J virus (! &; S & & B) K [ 0H & 0VI ; virus disease #2 ! & vagility 0 * 2M 7;B ,# I J 9 N> virus replication #2 B : [ 0H & 0VI ; viscosity 0 * N vaginosis A & E A visfatin 5 ' $N ) $2 133 English-Arabic
( 2 O X & 01 " & 01 U. wide spectrum (D 2 ) ! B H visible fluorescent ,# I & ,D - 2 & wild type 01 protein willingness to accept @; " 2 vitafood ,/ % < willingness to pay & "; K $6 0 H / D 1 > vitamer 0 " 3 % 91 &) & wind \ / ; (0 & wobble E% % / \1 H vitamin " 0 : B 91 &) & 3 &J ? : ? I %< ? & B X (/ " Z5-; 0; I: volicitin (3 - C &) 2 x chromosome x ,# R 8 voltage-gated ion channel 7;B 9 & " & 01 Q 9 @ 0 1 x receptor x 3 @ 2 & ,#I A J A * = x-linked disease x G# R G8 H & أِ volume 56 0H 2 / * x-ray x volume rendering Z 5M * x-ray crystallography x 01"-P 3 6; S & vomitoxin ,/ H $ % xanthine oxidase ( ) 1 2Jc voucher specimen 0 G B / 2 & 4 % & xanthophyll # $ 8 g 8 ) C vulgaris D I - (3 xenobiotic compound ? * ,# * E6J & W xenogeneic organ ,# * : B xenogenesis R & E * wagon E 0 " P @ 0 B xenogenetic organ ? 1 C ,# * : B wand * 8 xenogenic organ ? 1 C ,# * : B warfare 8 / E xenograft ,/ < " NH / ,# * "NH washer ( 8$& , - ) 0 @ ; / 0 ; 2 R & xenotransplant K *Q @ water activity & 01 " xenotropic virus 01 * 5 # C J K water soluble fiber & 0 I % waxy corn 01 " & - 9 N% Y weak interaction " : B $ weapon \ 2 y chromosome y ,# R G8 weapon of mass & - & 0 ; 2 yeast I & 5 destruction yeast artificial ,# B 8 9 & 5 ,# R 8 weaponization F ; 2 chromosome weaponize F+; 2 yeast episomal plasmid #& 2 9 & 5 & whiskers % / 6- " - / 0 ; " - yeast two-hybrid system * A ,# I NC ,/ & 5 Y 0 ; 2 white blood cell : 01 NJ Z white corpuscle : 01 NJ white mold disease ! Q $ " ! & z –DNA 4. " & whole-genome shotgun ,#> * & 2 ; 2 z-ring z 0 @ ; sequencing zearalenone ,/ H $ %) wide cross * A6 C J D 2 (,# B 8 134 English-Arabic zeaxanthin ( $ 8 0 91 &) C zoonotic 8 & ,# zigzag 4G " & H 5 zootoxin ,# $ % zinc finger protein ,# 8 5 ,# " 8 zygote 3 * / 0 >] zoaster / ; * ! &) 01 @ H & > zyme system ,# & Y (,# 2 zymogen Q + & zoonoses 8 & 01 ! &
135